This week's research: timing and the heart

A study published yesterday in JAMA Internal Medicine followed 2,737 women from the long-running Study of Women's Health Across the Nation (SWAN), tracking up to 20 years of health data. All of them had hot flashes or night sweats, none had heart disease at the start, and none had used hormone therapy before the study.

The finding: women who began hormone therapy during perimenopause or early postmenopause had a 22% lower risk of cardiovascular events - heart attack, stroke, heart failure, and related procedures - than women who never used it.

Two details matter most. First, timing. Women who started hormone therapy within 10 years of menopause onset saw the greatest benefit (about a 27% lower risk). Women who started more than 10 years after menopause saw no benefit. Second, the benefit was strongest among Black women - roughly half the risk - which is notable because hot flashes and night sweats tend to be more frequent and more severe in Black women.

Some context you deserve: in the early 2000s, the Women's Health Initiative trials raised alarms about hormone therapy and the heart, and a generation of women and doctors backed away from it. Much of that fear came from studying women who started hormones well past menopause. The FDA recently removed the broad black box warnings from these products, and this is the first US study of its kind to look at heart outcomes in women who start therapy during perimenopause or early postmenopause - which is when most women actually need it.

What you gain from this

First, honest context: this is an observational study, so it shows an association, not proof. An editorial in the same journal, from Mayo Clinic researchers, cautions that women who choose hormone therapy often differ from non-users in other healthy behaviors - that "healthy user bias" can flatter the results. The study's own authors are clear: these findings do not support using hormone therapy to prevent heart disease, and longer use still carries a real breast cancer risk that must be weighed.

Second, meaning: if you are in perimenopause or early menopause with hot flashes or night sweats that disrupt your sleep, your work, your life - this study is reassuring on the heart question. It does not say hormone therapy protects your heart. It says that starting it at the right time, for the right reason, was not linked to the cardiac harm many women still fear.

Third, action: if you have been white-knuckling through hot flashes because of headlines from twenty years ago, bring this study to your doctor. Timing is part of the conversation now, and the window matters. And if you are a Black woman reading this, the data here speak to you directly.

Sources: Wang Z, et al. JAMA Internal Medicine (2026), https://doi.org/10.1001/jamainternmed.2026.2922 - with editorial, https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2853616

That's the pattern here: the research, the plain-English meaning, and what to do with it. See you next time.

Dr. Herman Weiss

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health-care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor-patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Here's the idea. New research on menopause comes out constantly: hormones, brain health, bone, sleep, heart, mood. Most of it sits behind journal paywalls, written in language nobody outside medicine uses. Meanwhile you're left sorting through headlines and advice that contradicts itself.

This community exists to fix that. I read the science so you don't have to, and I translate the latest studies and clinical updates into clear, actionable insights - alongside proven best practices, practical lifestyle strategies, and the daily motivation to carry you through every step of your transition.

Let me show you what that looks like, with a study published just this week.

Late-breaking: HRT timing and your brain

A study published days ago in Alzheimer's & Dementia: The Journal of the Alzheimer's Association followed more than 183,000 postmenopausal women in the UK Biobank for an average of 13 years - the largest study of its kind. The finding: women who used hormone replacement therapy (HRT) had about a 10% lower risk of dementia and a 16% lower risk of Alzheimer's disease than women who never used it.

But the detail that matters most is timing. Women who started HRT between the ages of 46 and 56 saw the greatest benefit. The effect was also stronger in women who went through surgical menopause, and in women carrying the APOE4 gene linked to Alzheimer's.

What you gain from this

First, honest context: this is an observational study, so it shows an association, not proof. But it's one more piece of evidence that HRT is about far more than hot flashes - it may also play a role in protecting your long-term brain health.

Second, action: if you're in perimenopause or early menopause and weighing whether HRT is for you, timing is now part of that conversation. This is a question to bring to your doctor now, not in ten years. And if you've had surgical menopause or know you carry APOE4, this study is a concrete reason to have that conversation sooner.

That's the pattern you'll get here: the research, the plain-English meaning, and the "so what do I do with this."

Source: https://www.medicalnewstoday.com/articles/menopause-type-hrt-timing-influence-dementia-risk-large-study-alzheimers

What's ahead

As a member, you can expect the newest medical developments translated into language that makes sense, best practices you can trust, lifestyle strategies that fit real life, and steady encouragement along the way. Whether you're here to understand the latest science or looking for the motivation to thrive, this community is here with trusted, science-backed support for your journey.

Welcome aboard. I'm glad you're here.

Dr. Herman Weiss

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Why the standard structure fails this transition specifically

Most women move between two disconnected systems: a reproductive endocrinologist or OB/GYN manages PMOS during reproductive years, then somewhere in the 40s, care shifts toward primary care or a menopause-focused provider for the transition. Nothing in that handoff is designed to carry forward a PMOS-specific risk profile. The new provider typically starts from population-average perimenopause risk, not from “this patient has had two decades of elevated insulin resistance and needs a different monitoring baseline.”

That’s a structural gap, not a clinician failure. Nobody built the connective tissue between these two phases of care because they’re conventionally treated as separate conditions rather than one continuous metabolic story — and the fact that one of them just changed its name doesn’t fix that on its own.

What should actually be different, starting in the late 30s to early 40s

Earlier and more frequent metabolic monitoring. Fasting insulin and HOMA-IR, not just fasting glucose, tracked starting before perimenopausal symptoms even begin — establishing a real baseline rather than waiting for symptoms to trigger testing.

Cardiovascular risk assessment on an earlier timeline. Given the mechanistic overlap between PMOS-related and perimenopause-related cardiovascular risk factors, standard age-based screening triggers likely aren’t the right threshold for this population. Lipid panels and blood pressure trends deserve earlier and more frequent attention than population guidelines default to. [likely]

Vasomotor symptom severity treated as a metabolic signal, not just a comfort issue. Given the association between insulin resistance and vasomotor symptom severity, a woman with a PMOS history reporting unusually severe hot flashes may be reporting a metabolic escalation worth investigating, not just a quality-of-life complaint to manage symptomatically.

Body composition tracked with context, not just a scale number. The same amount of visceral fat gain likely means something different in a woman with two decades of prior insulin resistance than in a woman without that history — composition and trend matter more than a single weight or BMI number. [likely]

Continuity of care across the transition. The single highest-leverage fix is probably the simplest: a woman’s PMOS (PCOS) history should travel with her into perimenopause management as an active risk factor, not a closed chapter in an old chart. That requires either a single provider managing both phases, or a deliberate handoff that transfers the actual risk context, not just a diagnosis code.

Why this is a build problem, not just an awareness problem

Everything above requires a care structure willing to treat this transition as continuous rather than as two separate hand-offs — which is a genuinely different model than most existing menopause or PMOS care pathways are built around. That’s the specific gap I’ve been working on with the menopause program we’re developing at ProvationLife: designed explicitly around carrying a woman’s metabolic history forward instead of starting her risk assessment over at 45.

The throughline across this series

PMOS and perimenopause have been treated as two different chapters of a woman’s life, managed by two different parts of the healthcare system, using two different playbooks. The biology doesn’t actually support that split, and a new name for the first chapter doesn’t change the structural gap between them. It’s one metabolic story, and the transition between its two halves is exactly where care most often falls through the gap.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Symptom overlap creates a diagnostic blind spot

This is the first practical problem: irregular cycles, mood changes, weight redistribution toward the abdomen, and sleep disruption are symptoms of both PMOS and perimenopause. A woman with a long PMOS (PCOS) history entering her 40s may have her new perimenopausal symptoms attributed to “just your PMOS acting up again,” delaying recognition that a second, independent process has started. The reverse also happens — new metabolic symptoms in perimenopause get treated as generic “menopause” without anyone asking whether a PMOS-related insulin resistance baseline is making the picture worse than typical.

Vasomotor symptoms track with metabolic status, not just estrogen

Hot flashes and night sweats are usually framed purely as an estrogen-withdrawal phenomenon. But insulin resistance and elevated HbA1c are independently associated with greater frequency and severity of vasomotor symptoms, and more severe vasomotor symptoms are themselves linked to higher subsequent risk of a type 2 diabetes diagnosis. For a woman with pre-existing PMOS-related insulin resistance, this creates a plausible amplification loop: more baseline insulin resistance may mean rougher vasomotor symptoms, which is itself a signal of higher metabolic risk going forward, not just an uncomfortable symptom to manage separately. [likely]

Cardiovascular risk timing shifts earlier

Women with PMOS (PCOS) carry meaningfully elevated cardiovascular risk during reproductive years, largely driven by chronic insulin resistance, dyslipidemia, and inflammation. Whether that elevated risk specifically compounds with the cardiovascular changes of the menopausal transition is still being actively studied rather than settled, but the mechanistic overlap — insulin resistance, visceral fat gain, lipid changes — is the same pathway driving both. [likely] The practical implication is that cardiovascular risk assessment probably shouldn’t wait for standard age-based screening triggers in women with a PMOS history; the risk clock plausibly started earlier and doesn’t reset.

Body composition changes are not equivalent to typical perimenopausal changes

Every woman tends to gain visceral fat and lose muscle mass through the menopausal transition — that’s well established independent of PMOS history. In a woman whose insulin resistance was already elevated for decades, this shift is happening on top of already-reduced metabolic reserve, meaning the same degree of visceral fat gain may produce a larger jump in actual metabolic risk than it would in a woman without that history. [likely] This is a case where identical-looking body composition changes on the outside may represent meaningfully different internal risk trajectories.

Why this matters for how care should actually be structured

None of this means PMOS-history women need a fundamentally different perimenopause. It means the standard perimenopause conversation — hot flashes, mood, bone density, generic “watch your diet” — is missing the specific risk stratification this population needs. Treating a 45-year-old with a PMOS (PCOS) history the same way as a 45-year-old without one, from a metabolic monitoring standpoint, likely underestimates her actual risk trajectory. [likely]

Next in this series: what a care approach built around this compounding risk actually looks like — not generic menopause advice, and not a rehash of PMOS management, but something designed for the specific transition between the two.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

That’s not the same claim as “PMOS risk continues after menopause,” which has gotten some recent attention. It’s a more specific mechanistic point, and it’s the one that actually changes how this decade should be managed: perimenopause is an independent insulin-resistance event for every woman, PMOS history or not. When it happens to a woman whose insulin resistance was already elevated for the previous two decades, the two don’t just add — they compound.

Hit one: PMOS insulin resistance doesn’t go away

For the 50-70% of women with PMOS (PCOS) who experience insulin resistance, that resistance isn’t a reproductive-years-only phenomenon that resolves once cycles become less relevant. It persists. Fasting glucose, HbA1c, and insulin levels typically stay elevated well past the reproductive years, reflecting ongoing metabolic dysfunction rather than something tied specifically to ovulatory function. If you were borderline insulin resistant at 28, you’re not automatically fine at 45 just because the PMOS diagnosis feels like ancient history — or because it was still called PCOS when you first heard it.

Hit two: perimenopause is its own insulin-resistance event

Independent of any PMOS history, the menopausal transition itself drives insulin resistance in essentially every woman. Estrogen has real protective metabolic effects — on insulin sensitivity, fat distribution, and vascular function — and as estrogen declines through perimenopause, those protections erode. Abdominal fat mass increases even without significant weight gain, which is itself a marker of the metabolic shift underway rather than just an aesthetic change.

Why the combination is worse than either alone

This is the part that gets missed in most coverage of either topic separately: when menopausal insulin resistance lands on top of a pre-existing PMOS-related insulin resistance, the risk of triggering full metabolic syndrome is measurably higher than either factor would produce on its own. This isn’t two independent risks running in parallel — it’s a compounding effect, where the reproductive-years condition determines how much reserve capacity you have left when the second hit arrives. [likely]

What this means practically

If you’re a woman with a PMOS (PCOS) history heading into your 40s, the useful question isn’t “is my old diagnosis still relevant.” It’s “how much metabolic reserve do I actually have going into a transition that’s going to test it regardless.” That’s a very different framing than either “manage your PMOS” or “manage your menopause symptoms” treated as separate problems — which is how almost all existing content, mine included, has historically split this.

Next in this series: what actually shows up differently — clinically, not just theoretically — when PMOS-history women go through perimenopause compared to women without that history.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Read more

Subscribe now

Here are the eight stages, as published in The Lancet, with where things stand as of this writing.

Stage 1 — Publication and academic dissemination. The Health Policy paper itself, plus accompanying commentaries, clinical reviews, editorial correspondence, and updates to textbooks and educational materials. Status: underway. This is the stage we’re currently in.

Stage 2 — Resource development. Co-designed patient and health professional resources, in multiple languages, across different platforms and delivery formats. Status: early — this is the kind of thing that takes months to build properly, not weeks.

Stage 3 — Global communication and engagement. A structured rollout: society toolkits, multilingual clinician and patient materials, multimedia dissemination, professional education programs, and coordinated global events. Status: this is the stage where most patients and most clinicians would actually start hearing about it consistently — worth watching for over the next year.

Stage 4 — Integration within health care and health information systems. This is the unglamorous, structurally important one: getting the new terminology into electronic health records, including SNOMED CT coding, and engaging directly with EHR vendors and the universities and textbook publishers that train the next generation of clinicians. Status: this is the stage that determines whether your own chart says PMOS or still says PCOS five years from now. It’s also the stage most likely to lag, because EHR vendors move slowly and coding changes are notoriously bureaucratic. [likely]

Stage 5 — Policy and research alignment. Engagement with governments, research funders, journal editors, regulators, and industry (including pharma) to align research classification, publication norms, and funding categories with the new name.

Stage 6 — International classification and global bodies. Formal engagement with international bodies, including the World Health Organization, to get PMOS into disease classification systems like the ICD. This is a slow-moving, bureaucratically heavy stage almost by design — ICD updates aren’t fast anywhere in medicine.

Stage 7 — Transition and future refinement. A managed 3-year transition window, with ongoing monitoring, evaluation, and openness to refining the terminology further as evidence on subtypes accumulates. This stage is explicitly built to run in parallel with the others, not after them.

Stage 8 — Guidelines. Integration into the International Guideline — already used in 195 countries — which is scheduled for its next update in 2028.

Why 2028 is the actual date that matters

Everything before stage 8 is groundwork. The International Guideline is the document that actually shapes how clinicians worldwide are trained to diagnose and manage the condition, and it doesn’t get touched again until 2028. That’s the moment the reclassification either shows up as real, guideline-level clinical change, or it doesn’t. Everything between now and then — the toolkits, the EHR conversations, the ICD engagement — is infrastructure being built toward that date, not the outcome itself.

I’ll be honest about what I don’t know here: whether stage 4 (EHR integration) moves at the pace the authors are hoping for is genuinely uncertain, and it’s the stage I’d bet is most likely to slip, based on how slowly health IT systems generally move in general. [guessing] That’s exactly the kind of thing worth checking back on rather than assuming either way.

Next in this series: the skeptical case — why renaming a medical condition has historically had a mixed track record of actually changing clinical behavior, and what would have to be different this time for PMOS to avoid the same fate.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

I’m not going to pretend the answer is “everything,” and I’d be skeptical of anyone claiming it is. A name change published in May doesn’t rewrite an electronic health record system, retrain a primary care physician, or update an insurance billing code by August. That’s not a criticism of the process — it’s just how health system change actually moves, and it’s worth saying plainly instead of implying more has happened than has.

What’s real

The reclassification itself is substantive, not cosmetic. This wasn’t a rebrand — it was a multistep global consensus process spanning collaboration across 56 academic, clinical, and patient organizations, built on survey responses from more than 14,300 patients and health professionals worldwide. The name itself does real conceptual work: “polyendocrine” corrects the false impression that this is a single-hormone, ovary-only condition; “metabolic” puts insulin resistance and cardiovascular risk into the name instead of leaving them as an asterisk; and dropping “polycystic” removes a term that never accurately described the ultrasound finding in the first place — those aren’t pathological cysts, they’re arrested follicles, and the mislabeling has been a documented source of diagnostic confusion for decades. [certain]

What’s still mostly on paper

The authors were explicit that this doesn’t happen overnight. They laid out an 8-stage implementation plan, and as of today, we’re still in the early stages of it: publication and academic dissemination, and the beginning of resource co-design. The stages that actually touch daily clinical practice — EHR integration, clinician education programs, insurance and coding alignment, and formal adoption into disease classification systems like the ICD — are scheduled for later stages, with a managed 3-year transition window and full integration into the International Guideline not expected until 2028.

So if you ask your own OB/GYN or endocrinologist this week whether they’re charting “PMOS,” the honest answer for most of them right now is probably still “PCOS,” and that’s not a failure — it’s stage 1 of an 8-stage plan working roughly on schedule. [likely]

Why this piece exists

Most of the coverage in May treated the name change as the finish line. It wasn’t — it was the starting gun. The interesting question isn’t “did the name change,” which already happened and is done. It’s “does behavior change,” which is the thing the reclassification’s own authors said should be the actual measure of success, not terminology uptake on its own.

That’s what the rest of this series is going to track: not whether people are saying PMOS instead of PCOS, but whether the infrastructure underneath patient care — diagnosis speed, billing, guidelines, medical education — actually moves.

Next: the real roadmap, stage by stage, and what to actually watch for between now and 2028.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

This piece is the practical one — what to actually ask for, and how to get it taken seriously.

Why “ask your doctor” isn’t specific enough here

Most postpartum and primary care visits aren’t structured to surface pregnancy history as a risk factor unless you raise it. Obstetric records often don’t transfer cleanly into primary care systems, and even when they do, a GDM diagnosis from a prior pregnancy doesn’t automatically trigger a recall reminder the way, say, a mammogram due-date does. The default is that this falls through unless someone — you — makes it explicit.

The screening timeline, laid out

At the 6-week postpartum visit:

• A fasting glucose or HbA1c, not only the glucose tolerance test that may already be standard. If a GTT was done, ask what specifically was measured and get the actual numbers, not just “normal” or “abnormal.”

• Ask explicitly: “Can you flag gestational diabetes history in my chart as an ongoing risk factor, not a resolved pregnancy complication?” This is a five-second request that changes how future visits treat your history.

At 1 year postpartum:

• Repeat fasting glucose or HbA1c. This is the point where “it resolved after pregnancy” gets tested against “it’s still resolved a year later, away from the acute demands of a newborn and often with different activity and sleep patterns.”

Ongoing, every 1-3 years:

• The American Diabetes Association recommends screening every 1-3 years for women with a GDM history — this is guideline-supported, not something you’re inventing. [likely — confirm current ADA screening interval language before citing as guideline in the piece]

• This doesn’t need to be a separate visit. It can be added to an annual physical if you ask for it explicitly.

What to say if the initial answer is “you’re fine”

A single normal result sometimes gets treated as case-closed. If that happens:

• Ask what specific test was run and what the reference range was — “normal” on a random glucose is a much weaker clearance than a fasting glucose or HbA1c

• Reference the risk timeline directly: “GDM history is associated with meaningfully elevated diabetes risk for over a decade, sometimes longer — I’d like this tracked as an ongoing flag, not a one-time check”

• If your primary care provider isn’t tracking pregnancy history as a risk factor, that’s a reasonable moment to ask whether it’s in your problem list or just buried in old obstetric notes

What this isn’t

This isn’t a call to panic about a positive test that happened once, years ago. Most women with a GDM history do not go on to develop type 2 diabetes within the next decade — elevated risk isn’t the same as inevitability, and lifestyle factors (activity, weight trajectory, sleep) meaningfully modify the risk within that elevated baseline. The point of this series isn’t fear, it’s making sure the flag doesn’t get lost.

The through-line across this series

Pregnancy is one of the only times in a woman’s life she gets a mandatory, structured metabolic stress test — and one of the only times the result gets communicated back to her at all. Losing track of that result after delivery isn’t a small oversight. It’s discarding data that predicts real, modifiable risk a decade or more out. The fix isn’t more testing during pregnancy. It’s not stopping after it.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Subscribe now

The short version: GDM isn’t a pregnancy-specific glitch that happens to resolve. It’s a stress test that reveals a beta-cell reserve problem that was already there.

Pregnancy doesn’t create insulin resistance out of nothing — it exposes it

Every pregnancy pushes toward insulin resistance in the second and third trimester. Placental hormones — human placental lactogen, progesterone, cortisol, placental growth hormone — actively blunt insulin signaling in maternal muscle and fat tissue. This is normal physiology, not pathology. It’s how the body prioritizes glucose delivery to the fetus over maternal tissue.

For most women, pancreatic beta cells compensate by ramping up insulin secretion to match the resistance. Glucose stays controlled. No diagnosis, no problem.

GDM happens when beta cells can’t keep pace with the compensatory demand. That’s the key distinction: GDM isn’t caused by pregnancy hormones alone — every pregnant woman is exposed to those. GDM happens in women whose beta-cell reserve was already reduced, and pregnancy is simply the first physiologic stress large enough to unmask it. [likely]

Why that matters after delivery

Once the placenta is delivered, the hormonal load driving insulin resistance drops off within days. Glucose tolerance typically normalizes. This is where the story usually ends, clinically — normal postpartum glucose tolerance test, chart closed, “resolved.”

But the beta-cell reserve limitation that got exposed by pregnancy doesn’t resolve. It’s a durable trait, not a pregnancy-induced state. The stress of pregnancy is gone; the underlying vulnerability isn’t. That’s the mechanistic reason a “normal” postpartum GTT doesn’t mean “no risk” — it means the acute stressor has been removed, not that the susceptibility has.

This is also why the risk curve behaves the way it does in the data: elevated risk that’s highest in the years immediately after the affected pregnancy, gradually attenuating, but <cite index=”12-1”>remaining measurable more than 35 years later</cite> in some cohort data. A resolved stress test doesn’t erase what the stress test revealed.

The next stressor is coming regardless

Beta-cell reserve doesn’t only get tested by pregnancy. Age-related insulin resistance, weight gain, a second pregnancy, or simply the cumulative metabolic load of years — any of these can re-expose the same underlying limitation GDM already flagged once. The difference is that pregnancy came with built-in screening (routine glucose tolerance testing is standard prenatal care). The next stressor usually doesn’t.

That’s the practical argument for treating a GDM history as a permanent risk flag rather than a resolved pregnancy complication: you already have the test result. It was positive. Nothing about the underlying biology changed when the pregnancy ended — only the stressor that was exposing it.

What this means clinically

If GDM is a marker of reduced beta-cell reserve rather than a pregnancy-specific event, the follow-up logic changes:

• A normal postpartum GTT is a snapshot, not a clearance

• Risk doesn’t reset to baseline — it starts elevated and stays elevated for decades

• Periodic rescreening isn’t overcautious monitoring, it’s checking a trait that’s known to be present

Next in this series: the actual protocol — what to ask for, when, and how to get a clinician to treat GDM history as the durable flag the evidence says it is, not a closed chapter.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Not “slows down.” Stops. For most women, that six-week visit is the last systematic look anyone takes at your metabolic health — not just for months, but often for years. Sometimes forever, unless something else forces the issue.

I want to walk through why that’s a problem, because pregnancy isn’t a metabolic non-event that resolves on its own once the baby arrives. It’s closer to a stress test.

Pregnancy is an induced insulin-resistant state

By the third trimester, placental hormones — human placental lactogen, progesterone, cortisol — deliberately push your cells toward insulin resistance. This isn’t a malfunction. It’s the mechanism that shunts glucose toward the fetus instead of your own muscle and fat tissue. Every pregnant woman experiences some version of this shift.

For most women, insulin sensitivity returns to baseline within weeks of delivery. For a meaningful subset, it doesn’t fully resolve — and gestational diabetes is the clinical marker that flags who’s most likely to be in that second group.

“It resolved” isn’t the same as “it’s fine”

Here’s the part that doesn’t get said out loud enough: a normal postpartum glucose tolerance test doesn’t mean the risk is gone. It means the acute stress test is over. Women with a history of gestational diabetes have a risk of developing type 2 diabetes within 10 years that’s substantially higher than women without that history — some cohort data puts it at roughly 7 to 10 times higher [likely — figures vary by study population and follow-up duration]. That risk doesn’t announce itself. It accumulates quietly, without symptoms, while nobody’s checking.

The standard of care after a GDM pregnancy technically includes a glucose tolerance test at 4–12 weeks postpartum. What it doesn’t reliably include is anyone telling you why that’s the last checkpoint, or making sure it actually happens once you’re absorbed into the chaos of a newborn.

Why this gets missed

It’s not negligence — it’s structural. Obstetric care is built around delivery as the finish line. Once you’re discharged from OB care, metabolic follow-up becomes primary care’s job, and primary care often doesn’t have pregnancy history flagged as a reason to screen early or often. You fall into a gap between two systems, both of which assume the other one is watching.

What to actually ask for

If you had gestational diabetes, or PCOS going into pregnancy, or a large-for-gestational-age baby, or a strong family history of type 2 diabetes:

• Ask for a fasting glucose and HbA1c at your 6-week visit, not just a glucose tolerance test if that was already done

• Ask your primary care provider to flag pregnancy history in your chart so future screening isn’t reset to “average risk”

• Get metabolic labs rechecked at 1 year postpartum, not “whenever it comes up”

None of this requires a new drug or a new supplement. It requires someone treating pregnancy as data instead of a closed chapter.

This is the first piece in a new series picking up where the PCOS/PMOS work leaves off — the postpartum period as the next chapter of the same metabolic story, not a separate one.

Subscribe now

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

The gut microbiome went from a niche corner of microbiology to a full-blown consumer category in about a decade — stool test kits, “diversity score” apps, strain-specific probiotics stacked three deep on your bathroom counter. Before I tell you what’s real, I want to tell you what isn’t, because the fake stuff is where the money is.

Leave a comment

Subscribe now

Part One: The Hype, Stress-Tested

“Send us your stool, we’ll tell you what’s wrong with your gut.”

No, they can’t — not reliably. A 2026 Communications Biology study sent the same combined stool sample to 21 direct-to-consumer gut microbiome testing kits from 7 different companies. Results were inconsistent both between companies and, in some cases, within the same company retesting its own protocol. This was under laboratory-controlled conditions — the best-case scenario for these tests. Real at-home samples, subject to uneven collection and shipping delays, would be expected to perform worse, not better. There is currently no consensus definition of a “healthy” microbiome to test against in the first place, which is part of why the health scores these companies generate vary so widely. If you’ve paid for one of these kits and gotten a “leaky gut” or “dysbiosis” score, that number was not built on a validated reference standard.

“Take this 20-strain probiotic to restore your microbiome.”

A 2026 systematic review and meta-analysis in BMC Medicine pooled 22 randomized controlled trials, 1,068 healthy subjects, specifically testing whether probiotic supplementation increases gut microbiota diversity in people who are not sick. The finding: probiotic supplementation has a limited effect on microbiome diversity in healthy individuals. Where probiotics do show real, reproducible benefit, it’s strain-specific and condition-specific — for example, single-strain Lactobacillus rhamnosus GG and Bifidobacterium longum trials show measurable symptom reduction in irritable bowel syndrome, and even there, effect sizes vary by dose and duration in ways that don’t support a “more strains is better” marketing pitch. A 40-billion-CFU, 20-strain shotgun blend sold to a healthy person to “diversify the microbiome” is not what the evidence supports. That’s a supplement industry inference, not a trial finding.

“Diet soda doesn’t count against you because it has zero calories.”

Also not clean. A 2022 Cell randomized controlled trial (Suez et al., 120 healthy adults, 2 weeks, doses below the acceptable daily intake) found that saccharin and sucralose significantly impaired glycemic responses via microbiome-mediated changes — and the effect was personalized, meaning your particular gut flora determines how much a given sweetener disrupts your glucose handling. Aspartame and stevia did not show the same glycemic effect in this trial. This is one RCT, not a settled verdict on all non-nutritive sweeteners — but “it’s zero-calorie so it’s metabolically inert” is not a claim this data supports for saccharin or sucralose specifically.

Part Two: What The Evidence Actually Supports

Here’s the real protocol — evidence-graded, with the dose and duration each claim is actually built on.

1. Fermented foods, not fiber alone, is what moved the needle in the best controlled trial we have. Stanford’s 2021 Cell trial (Wastyk/Sonnenburg/Gardner, 36 healthy adults, 10-week randomized diet) is the reference study here. The fermented-food arm ramped from roughly 0.4 servings/day at baseline to 6.3 servings/day by the end of the maintenance phase (yogurt, kefir, fermented cottage cheese, kimchi, fermented vegetables, vegetable brine drinks, kombucha) and showed a measurable increase in microbial diversity and a decrease in inflammatory markers — with a dose-response relationship: more servings, larger effect. The high-fiber arm (legumes, seeds, whole grains, nuts, vegetables, fruits) did not increase microbial diversity or reduce inflammation over the same 10 weeks, despite the researchers expecting the opposite going in. Fiber still improved carbohydrate-degrading capacity and short-chain fatty acid production — it’s not useless — it just didn’t do the diversity/inflammation work fermented foods did, at least not in 10 weeks.

2. If you’re going to increase fermented foods, ramp slowly. The 6.3-servings/day endpoint was reached gradually over 10 weeks, not on day one, and some participants reported bloating during the ramp-up. Going from zero to six servings overnight is not the protocol that was tested.

3. Reconsider sucralose and saccharin specifically if you’re managing insulin resistance. Given the Suez et al. mechanism, and given that this population is already managing glucose regulation, the more conservative sweetener choices based on current RCT data are stevia or aspartame over sucralose or saccharin — while noting that RCT evidence on long-term outcomes here is still thin, and this is a two-week mechanistic trial, not a multi-year clinical outcomes study.

4. Skip the DTC stool test as a health-optimization tool. Save the money. If there’s a genuine clinical indication (refractory GI symptoms, suspected infection, IBD workup), that’s a conversation for a gastroenterologist ordering a clinically validated test — not a $200 wellness-brand kit promising a “diversity score.”

5. Probiotics: match the strain to the problem, don’t blanket-dose for “gut health.” If there’s a specific indication — IBS symptoms, post-antibiotic support — a single, evidence-matched strain at a studied dose is a more defensible choice than a proprietary multi-strain blend with no trial behind the exact combination on the label.

5 Next steps

1. Increase fermented food intake toward ~6 servings/day, ramped gradually over ~10 weeks.
Supported by: Stanford Cell 2021 RCT (Wastyk/Sonnenburg/Gardner, n=36) — fermented-food arm went from ~0.4 to 6.3 servings/day and showed increased microbial diversity + reduced inflammatory markers, with a dose-response (more servings → larger effect). [certain]
Caveat: n=36, healthy adults, not an insulin-resistant/PMOS population. [likely]

2. Don’t rely on high fiber alone as a “microbiome diversity” intervention.
Supported by: same trial — the high-fiber arm did not increase microbial diversity or reduce inflammation over 10 weeks, despite researchers expecting it to. [certain]
Fiber still improved carbohydrate-degrading capacity and SCFA production — so it’s a “keep it, but don’t oversell it” item, not a “drop it.” [certain]

3. Reconsider sucralose and saccharin specifically in insulin-resistant patients.
Supported by: Suez et al., Cell 2022 RCT (n=120, 2 weeks) — sucralose and saccharin significantly impaired glycemic response via microbiome-mediated mechanism; aspartame and stevia did not show the same effect in this trial. [certain]
Caveat: 2-week mechanistic trial, not a long-term outcomes study — frame as a conservative preference, not a proven clinical directive. [likely]

4. Don’t order or recommend direct-to-consumer stool microbiome tests for general “gut health optimization.”
Supported by: Communications Biology 2026 — 21 DTC kits from 7 companies given the same stool sample produced inconsistent results, both between and within companies, under best-case lab conditions. [certain]
This is an actionable don’t, which is a legitimate action item — it saves the reader money and stops a decision being made on non-reproducible data.

5. If recommending a probiotic, match strain to indication and studied dose — skip broad multi-strain “gut health” blends for otherwise-healthy people.
Supported by: BMC Medicine 2026 meta-analysis (22 RCTs, n=1,068 healthy adults) — probiotics showed limited effect on microbiome diversity in healthy populations. Strain-specific benefit exists for defined conditions (e.g., L. rhamnosus GG, B. longum for IBS symptoms), not as a general diversity booster. [certain]

Sources

• Servetas et al., “Evaluating the analytical performance of direct-to-consumer gut microbiome testing services,” Communications Biology, 2026

• BMC Medicine systematic review/meta-analysis, “Effect of probiotic supplementation on gut microbiota diversity in healthy populations,” 2026 (22 RCTs, n=1,068)

• Maslennikov et al., strain-specific probiotic meta-analysis for IBS, J. Clin. Med., 2026

• Suez, Cohen, Valdés-Mas et al., “Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance,” Cell, 2022

• Wastyk, Fragiadakis, Sonnenburg, Gardner et al., “Gut-microbiota-targeted diets modulate human immune status,” Cell, 2021

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

A New York Times Magazine cover story this week actually gets the science right, and it’s more interesting — and more uncomfortable — than the influencer version. I want to walk you through what it actually found, because the real story is not “reduce your inflammation.” It’s “we don’t yet know how to safely act on what we’re learning, and pretending otherwise has a body count.”

The trial that should be the headline, not a footnote

In 2011, researchers ran a large trial testing an anti-inflammatory drug against atherosclerosis — the plaque buildup that causes heart attacks and strokes. Over four years, the drug cut the risk of heart attack or stroke by about 15%. That was the first real proof that inflammation itself causes cardiovascular disease, not just rides along with it. Patients on the drug even had fewer cancer deaths.

Here’s the part that gets buried: the same patients had a small but real increase in deaths from infection and sepsis. Turning down inflammation system-wide also turns down your ability to fight actual pathogens. The drug ended up approved only for narrow, specific uses because of exactly that trade-off.

This is the single most important fact in the entire inflammation conversation right now: inflammation is vital and harmful using the exact same mechanism. There is no clean “off switch” that only removes the bad part. Anyone selling you a simple “reduce your inflammation” protocol has quietly skipped past the hardest, most inconvenient finding in the research.

Subscribe now

Share

The measurement problem

Right now, the standard blood test for inflammation measures one protein, produced by your liver, that tells you nothing about where the inflammation is or why it’s there. That’s about to change — researchers are piloting real-time inflammation monitors, similar in concept to a continuous glucose monitor, tracking several inflammatory markers at once.

I think this is genuinely exciting. I also think it’s a preview of a problem, not a solution. Our ability to measure inflammation continuously is about to outrun our ability to know what any given pattern actually means or what to do about it. A five-protein readout is only useful once we know which patterns predict which diseases, and which interventions actually move them safely. We are not there yet. If you get access to one of these devices before the interpretive science catches up, you’ll have more data and no better answers — which is its own kind of anxiety-inducing.

What the article gets right about GLP-1s — and where it stops

One of the more interesting threads: physicians prescribing Ozempic and Wegovy for diabetes and weight loss are hearing from patients that arthritis, Crohn’s, chronic pain, and other seemingly unrelated conditions are improving. Initially this got chalked up to weight loss alone. But a large cardiovascular trial found Wegovy cut cardiac death risk by 20% — and weight loss only explained about a third of that benefit. Something about these drugs is acting directly on inflammatory pathways, independent of the scale.

But here’s the discipline I want you to take from this: given the same neural-inflammation link, researchers hoped GLP-1s might help Alzheimer’s and Parkinson’s. The trials so far haven’t shown consistent benefit. Same drug class, same theoretical mechanism — and it didn’t transfer. That’s exactly the kind of result that should make all of us slower to assume “anti-inflammatory” means “helps everything.”

The piece the article missed entirely

The article’s own central metaphor, from a Washington University neuroimmunologist, is chronic inflammation as a road crew that never leaves your street after finishing a repair. It’s a good metaphor. But it raises an obvious question the article never asks: who’s supposed to call the crew off the job?

There’s an actual answer, and it’s been documented for over twenty years: the vagus nerve carries a “something’s wrong” signal to your brain, and carries a “stand down” signal back to your immune system, telling inflammatory cells to stop once a threat has passed. Researchers call it the inflammatory reflex. It’s real, it’s replicated, and it’s a plausible mechanism connecting nervous system tone to inflammatory regulation — worth watching closely, not yet proven as a clinical lever at the precision level this whole conversation is asking for. But it’s a genuinely strange omission from a major piece asking why the inflammatory fire won’t go out, when the body’s own dispatcher has been sitting in the literature the whole time.

Where this leaves you

I know that’s an unsatisfying ending for a post about the future of medicine. But the least exciting answer in the entire article is also the one every single researcher quoted in it converges on anyway: sleep, diet, movement, and an actual physician who knows your history — not because it’s a cop-out, but because it’s the one part of this story that doesn’t carry the same risk profile as the drug trial above.

We are building real infrastructure toward a genuinely more personalized, preventive model of medicine. Building the infrastructure is not the same as being ready to use it. I’d rather tell you that plainly than sell you a protocol before the science underneath it exists.

If you want me to go deeper on the vagal tone / inflammatory reflex mechanism specifically — including what current research does and doesn’t support about influencing it — reply and let me know. That’s a piece I’d want to source properly before writing, not rush out this week.

Leave a comment

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

Executive Summary

• ESG formally endorses renaming PCOS to “polyendocrine metabolic ovary syndrome (PMOS),” backed by a 56-organization consensus — opinion-driven, zero new clinical data, but real downstream implications for patient materials and coding. (PMID 42367168)

• The most rigorous PCOS-drug synthesis this week: liraglutide has the deepest PCOS-specific evidence among incretins; semaglutide’s evidence is thin but promising; tirzepatide has zero PCOS-specific data — any use today is extrapolation, full stop. (PMID 42106472)

• A companion commentary flags an unresolved safety gap: GLP-1 use in PCOS adolescents has no reproductive-outcome data and a theoretical, unproven bone-density risk during peak bone-mass years. (PMID 42364709)

• Two diet papers converge on modest, actionable guidance: a 6-week RCT favors early time-restricted eating (8am–6pm) over mid-day TRE for lipids; a 38-study systematic review confirms diet broadly helps weight/insulin but not consistently lipids or inflammation. (PMID 42371138, 42371137)

• A small, retrospective, supplement-industry-adjacent pilot claims a specific 3.6:1 myo-inositol:D-chiro-inositol ratio improves IVF outcomes in PCOS — promising direction, weak design, not yet practice-changing. (PMID 42334964)

Read more

Where Endocrinology Meets Reproduction

We have now covered three of the seven endocrine axes implicated in PMOS. The thyroid — a comorbid amplifier with meaningful autoimmune prevalence. The insulin-IGF-1 axis — the metabolic engine room and primary pathophysiological driver. The HPA axis — the stress-adrenal layer that compounds the hyperandrogenic and anovulatory phenotype in a meaningful subset of patients.

Part Four brings us to the axis that most physicians think of first when they hear the words polycystic ovary — the hypothalamic-pituitary-ovarian axis, the HPO axis. And here I want to make a clinical argument that is central to everything this series has been building toward: the HPO axis in PMOS is not the cause of the disease. It is the anatomical site where the disease becomes clinically visible.

The neuroendocrine dysregulation of the HPO axis in PMOS — the elevated LH pulse frequency, the blunted FSH amplitude, the LH:FSH ratio inversion, the failure of follicular selection and ovulation — these are not primary defects. They are the reproductive expression of the insulin resistance, adrenal androgen excess, and HPA dysregulation we have already characterized. Understanding this distinction is not merely academic. It determines whether we treat the cause or the symptom — and whether our patients get better or simply get managed.

That said, the HPO axis dysfunction in PMOS is real, measurable, and in some contexts requires direct therapeutic attention — particularly when the clinical goal is ovulation induction or fertility. This installment will map the full neuroendocrine architecture, explain the GnRH pulse abnormality in molecular and clinical terms, assess the gonadotropin story and its therapeutic implications, and deliver a referenced review of the pharmacological and nutraceutical landscape targeting this axis.

1. The HPO Axis: Architecture and Normal Reproductive Physiology

The GnRH Pulse Generator

At the apex of the HPO axis sits the GnRH pulse generator — a network of approximately 1,000–2,000 kisspeptin/neurokinin B/dynorphin (KNDy) neurons in the arcuate nucleus of the hypothalamus that drive episodic, pulsatile secretion of gonadotropin-releasing hormone (GnRH) into the hypothalamic-hypophyseal portal circulation.¹ This pulsatility is not incidental. It is required for normal gonadotropin secretion. Continuous GnRH exposure — as exploited therapeutically by GnRH agonists — actually suppresses the pituitary through receptor downregulation. The pulse is the signal.

The frequency and amplitude of GnRH pulses encode distinct downstream hormonal messages:

▸ High-frequency GnRH pulses (approximately every 60–90 minutes in the late follicular phase) favor LH synthesis and secretion

▸ Lower-frequency GnRH pulses (every 2–4 hours in the luteal phase) favor FSH synthesis and secretion

▸ Pulse amplitude modulates the absolute magnitude of gonadotropin release

This frequency encoding is the mechanism by which the HPO axis generates the LH surge at ovulation (peak frequency), maintains luteal progesterone support (lower frequency), and — crucially — selects the dominant follicle through FSH-driven granulosa cell maturation (intermediate frequency with rising amplitude).

The KNDy Neuron: The Master Regulator We Mostly Ignored Until Recently

The discovery that KNDy neurons — co-expressing kisspeptin, neurokinin B (NKB), and dynorphin — constitute the GnRH pulse generator was one of the most significant advances in reproductive neuroendocrinology of the past two decades.² These three neuropeptides form an autocrine regulatory circuit within the arcuate nucleus:

▸ Kisspeptin stimulates GnRH release (via Kiss1R on GnRH neurons) — the “go” signal

▸ Neurokinin B (NKB) stimulates KNDy neuron activity via NK3R — the “amplifier”

▸ Dynorphin inhibits KNDy neuron activity via κ-opioid receptors — the “brake”

The balance between NKB-driven activation and dynorphin-mediated inhibition determines pulse frequency. Progesterone, in the luteal phase, acts primarily through dynorphin to slow the pulse generator and favor FSH. Estradiol and testosterone modulate both limbs. And — critically for PMOS — so do insulin, leptin, and androgens. The KNDy neuron is the convergence point where metabolic and reproductive signaling intersect at the molecular level.

Normal Follicular Development: The FSH Window

Each menstrual cycle, a cohort of antral follicles (2–5 mm) enter the FSH-sensitive window. Over 5–7 days of progressive FSH stimulation, one follicle — the one with the highest FSH receptor density and the most responsive granulosa cells — is selected as the dominant follicle. As it grows, it produces increasing estradiol, which feeds back to suppress FSH (reducing the pool available to non-dominant follicles) while simultaneously sensitizing the pituitary to the LH surge trigger. The LH surge — triggered when estradiol reaches a threshold — drives final follicular maturation, oocyte meiotic resumption, and ovulation 36–40 hours later.³

This sequence requires precise timing of FSH amplitude, LH pulse modulation, and estradiol feedback. It is a remarkably narrow physiological window. In PMOS, multiple inputs perturb this window simultaneously — and the follicles that arrest in the antral stage are not diseased follicles. They are follicles that received the wrong signal at the wrong time from a dysregulated hormonal environment. The follicles are competent. The environment is not.

2. HPO Axis Dysregulation in PMOS: The Full Mechanistic Picture

The Central Abnormality: GnRH Pulse Frequency Elevation

The foundational neuroendocrine observation in PMOS — first characterized by Crowley and colleagues at Massachusetts General Hospital in seminal work spanning the 1980s and 1990s — is that women with PCOS demonstrate persistently elevated LH pulse frequency, with LH pulses occurring approximately every 60 minutes compared to 90–120 minutes in normal women in the early follicular phase.⁴ This LH pulse frequency elevation is present across all PMOS phenotypes and is not explained by body weight, insulin resistance, or androgen levels alone — it appears to represent an intrinsic, possibly genetic, abnormality of the GnRH pulse generator.

The consequences of this elevated pulse frequency are precisely what we observe clinically:

Elevated GnRH pulse frequency (every ~60 min instead of ~90–120 min)

→ pituitary preferentially synthesizes and secretes:

LH excess: elevated LH amplitude and mean LH concentrations

→ simultaneously suppresses:

FSH: reduced FSH synthesis (high-frequency GnRH disfavors FSH beta-subunit gene expression)

→ producing the cardinal hormonal signature:

Elevated LH:FSH ratio (>2:1, often >3:1 in PMOS) — historically a diagnostic criterion

→ which drives:

LH hyperstimulation of ovarian theca cells → androgen excess (amplified by insulin-IGF-1 axis)

→ while:

Inadequate FSH fails to stimulate granulosa cell aromatase sufficiently → impaired estradiol conversion

→ resulting in:

Follicular arrest at 4–9 mm: no dominant follicle selected, no ovulation, no corpus luteum, no progesterone

This cascade explains the anovulatory phenotype entirely from a neuroendocrine standpoint. But it does not explain why GnRH pulse frequency is elevated in PMOS. For that we need to understand the feedback architecture — and where it breaks down.

The Progesterone Feedback Failure: The Missing Brake

In normal physiology, progesterone produced by the corpus luteum after ovulation slows the GnRH pulse generator through dynorphin — the “brake” we described above. This negative feedback is critical for resetting the HPO axis and initiating the next follicular phase with appropriately low LH pulse frequency.

In PMOS, ovulation is absent or infrequent. There is no corpus luteum. There is no luteal progesterone. And without progesterone-mediated dynorphin activation, the brake on the GnRH pulse generator is chronically disengaged. The pulse frequency remains elevated. LH remains dominant. FSH remains suppressed. The follicles remain arrested.

This creates a self-perpetuating neuroendocrine loop that is mechanistically distinct from — but synergistic with — the insulin-IGF-1 and HPA axes we have already covered. It does not require ongoing metabolic input to sustain itself once established. And it is precisely why some lean, metabolically healthy-appearing women still have PMOS: the neuroendocrine loop can run independently once the progesterone feedback failure is entrenched. Insulin resistance may have initiated the dysregulation, but the HPO axis then maintains it through its own internal dynamics.

The Androgen Amplification Loop at the Hypothalamus

Androgens act directly on KNDy neurons to further elevate GnRH pulse frequency. This has been elegantly demonstrated in animal models and inferred in human studies: testosterone and its non-aromatizable analog dihydrotestosterone (DHT) reduce the sensitivity of KNDy neurons to progesterone-mediated dynorphin inhibition.⁵ In practical terms: the androgen excess produced by LH-driven thecal stimulation feeds back to the hypothalamus and further accelerates the GnRH pulse generator. This is the androgen-amplified HPO loop:

The PMOS Neuroendocrine Amplification Loop — Self-Perpetuating Once Established

1. Elevated GnRH frequency → LH excess → thecal androgen excess

2. Androgen excess → reduces progesterone feedback sensitivity at KNDy neurons

3. Reduced progesterone sensitivity → dynorphin brake disengaged → GnRH frequency stays elevated

4. No ovulation → no corpus luteum → no progesterone → further progesterone feedback failure

5. Cycle repeats, deepening with each anovulatory cycle

External inputs that further drive this loop: insulin (sensitizes thecal cells AND directly stimulates hypothalamic LH release), cortisol excess (impairs progesterone receptor sensitivity), and sleep disruption (disrupts diurnal GnRH patterning).

The Estrogen Paradox: Unopposed Estrogen and Endometrial Risk

A critically underappreciated clinical consequence of chronic anovulation in PMOS is unopposed estrogen exposure to the endometrium. In a normal cycle, the follicular phase’s estrogen exposure is followed by 12–14 days of progesterone dominance from the corpus luteum, which matures and then sheds the endometrium. In anovulatory PMOS, estrogen stimulation is continuous and progesterone never arrives.

The consequence is endometrial hyperplasia, with a well-documented progression risk to endometrial cancer. Women with PCOS have approximately a threefold increased risk of endometrial cancer compared to age-matched controls.⁶ This risk is not theoretical and it is not distant — premenopausal endometrial cancer in PMOS patients represents a real clinical threat that is directly addressable through cycle regulation. Every PMOS patient with oligomenorrhea or amenorrhea must have her endometrium monitored and protected. This is one of the non-negotiable clinical imperatives of managing this condition, and it belongs in the HPO axis chapter because it is a direct consequence of the anovulatory loop we have just described.

3. LH, FSH, and the Gonadotropin Story: What the Numbers Actually Tell Us

The LH:FSH Ratio: Useful but Misunderstood

An elevated LH:FSH ratio — classically defined as >2:1 or >3:1 — was historically included as a diagnostic criterion for PCOS and remains widely used as a screening tool. It reflects the GnRH pulse frequency elevation we have described. But its clinical interpretation requires nuance that is frequently missing in practice.

LH:FSH Ratio: What It Tells You

LH:FSH Ratio: What It Does Not Tell You

Confirms GnRH pulse frequency elevation when markedly elevated (>3:1)

Whether the primary driver is neuroendocrine, insulin-mediated, or androgen-driven

Supports PMOS diagnosis when elevated in clinical context

Normal ratio does NOT exclude PMOS — ratio is normalized in many metabolically treated patients

Helps distinguish PMOS from hypothalamic amenorrhea (low LH:FSH) and premature ovarian insufficiency (elevated FSH)

Ratio varies significantly with cycle timing, obesity (blunts LH amplitude), and assay methodology

Tracks treatment response — ratio normalization correlates with ovulatory restoration

Elevated ratio alone is not sufficient for PMOS diagnosis without clinical and metabolic context

One particularly important practical point: obesity suppresses LH pulse amplitude through leptin-mediated and adipokine-mediated effects on pituitary gonadotroph function. A significantly obese PMOS patient may have a normal or even low-normal LH:FSH ratio despite severe underlying GnRH pulse frequency elevation — because the amplitude signal is blunted even while the frequency is pathologically high. Relying on LH:FSH ratio alone in obese patients systematically underestimates HPO axis dysregulation.

Anti-Müllerian Hormone (AMH): The Biomarker That Changed PMOS Diagnostics

Anti-Müllerian hormone — produced by granulosa cells of preantral and small antral follicles — is the most sensitive and specific biochemical marker of ovarian follicle reserve and, in PMOS, of follicular excess and arrest. AMH levels in PMOS patients are typically 2–4 times higher than normal — reflecting the dramatically increased number of small antral follicles that characterize the arrested follicular cohort.⁷ AMH has now largely supplanted antral follicle count (AFC) on ultrasound as the preferred marker of polycystic ovarian morphology (PCOM) and is increasingly being incorporated into updated PMOS diagnostic criteria.

AMH in PMOS also has pathophysiological significance beyond its role as a diagnostic biomarker. Elevated AMH:

▸ Directly inhibits FSH receptor expression on granulosa cells, reducing follicular responsiveness to FSH stimulation and deepening follicular arrest⁸

▸ Acts on GnRH neurons — a recently characterized pathway suggesting that elevated AMH from the arrested follicle pool directly stimulates the hypothalamic GnRH pulse generator, contributing to the elevated LH pulse frequency⁹

▸ Crosses the blood-brain barrier (in animal models) and may act centrally to impair the kisspeptin/GnRH signaling cascade

This AMH-GnRH connection represents one of the most significant recent mechanistic insights in PMOS biology. It provides a previously missing link between the ovarian phenotype and the hypothalamic dysfunction — suggesting that the follicles themselves participate in maintaining the neuroendocrine dysregulation through AMH hypersecretion. The ovary is not merely the victim of a dysregulated hypothalamus. Through AMH, it actively contributes to perpetuating the hypothalamic abnormality. This is a bidirectional relationship — and it is a very recent discovery that is reshaping how we understand PMOS pathophysiology.

A 2023 study by Castellano et al. in Nature demonstrated that prenatal AMH excess in mice reproduces the full PMOS neuroendocrine phenotype — elevated LH pulse frequency, GnRH hypersecretion, and anovulation — entirely through a central (hypothalamic AMH receptor) mechanism.¹⁰ The clinical implications of this are still being worked out, but it fundamentally challenges the assumption that HPO axis dysregulation in PMOS is purely secondary to metabolic or androgen-mediated inputs.

4. The HPO Axis Across the Reproductive Lifespan: PMOS Does Not End at Menopause

I addressed this issue directly in the post that launched this series, but it bears full clinical elaboration here, because the HPO axis is central to the claim that PMOS “resolves” with menopause — a claim I described then as dangerous, and that the science does not support.

What Actually Happens to the HPO Axis in Perimenopause with PMOS

As ovarian follicle reserve declines in perimenopause, FSH rises (loss of follicular inhibin B suppression), LH rises, and the LH:FSH ratio that was elevated in PMOS may actually normalize or invert. AMH falls as follicle number diminishes. Cycles that were irregular in the PMOS reproductive years may paradoxically become more regular in perimenopause before cessation — a frequently cited clinical observation that has led some practitioners to conclude that PMOS “improves”.

This is a phenotypic change, not a resolution of the underlying disease. The insulin resistance does not remit with menopause — it worsens, driven by the loss of estrogen’s insulin-sensitizing effects. The adrenal androgen contribution does not cease — DHEA-S declines gradually but the androgen:estrogen ratio shifts unfavorably in the post-menopausal period. The cardiovascular risk, the visceral adiposity tendency, the dyslipidemia, the NAFLD/MASLD risk — none of these resolve. They accelerate.

A 2011 prospective cohort study by Schmidt et al. followed women with PCOS through menopause and demonstrated that the metabolic risk profile — insulin resistance, dyslipidemia, visceral adiposity — remained significantly elevated in postmenopausal former PCOS patients compared to controls, independent of BMI.¹¹ The HPO axis gonadotropin abnormalities may normalize. The metabolic disease does not.

The woman who is told at 47 that her PCOS is “getting better” because her cycles have regularized and her LH:FSH ratio has normalized is being given information that is technically partially accurate and clinically profoundly misleading. She is entering the highest-risk metabolic decade of her life without the monitoring and intervention framework she needs.

HPO Axis Changes in PMOS Across the Reproductive Lifespan — What They Mean

Reproductive years: Elevated LH:FSH, elevated AMH, anovulation, androgen excess, follicular arrest — the full classical phenotype

Perimenopause: LH:FSH ratio may normalize as FSH rises; AMH falls; cycles may transiently regularize — MISLEADINGLY APPEARS to improve

What is actually happening in perimenopause: Insulin resistance worsening; cardiovascular risk accelerating; endometrial protection concern shifting from progesterone-deficiency risk to HRT decision

Postmenopause: HPO axis gonadotropin abnormalities resolved — metabolic disease fully intact and often worsened

Clinical imperative: The resolution of HPO axis phenotype markers DOES NOT signal resolution of PMOS. Metabolic monitoring and intervention must continue through and beyond the menopausal transition.

5. Laboratory Assessment of the HPO Axis in PMOS

The Core Gonadotropin Panel

LH and FSH — Timed Correctly

LH and FSH should be measured in the early follicular phase (days 2–5) in women with any cycle activity, or at any time in anovulatory women. Timing matters enormously — mid-cycle LH values are physiologically elevated and misleading, and luteal phase values reflect corpus luteum feedback that does not apply in anovulatory PMOS. Always record cycle day on the requisition. An LH:FSH ratio above 2:1 with clinical context supports PMOS. A normal ratio does not exclude it.

AMH (Anti-Müllerian Hormone)

AMH can be measured on any cycle day (it does not vary significantly with the menstrual cycle — an advantage over AFC ultrasound) and is the preferred marker of ovarian follicular reserve and follicular excess in PMOS. AMH above 4.7–5.0 ng/mL (using the Beckman Coulter Generation II assay, the most widely validated) is consistent with PCOM. Levels above 10 ng/mL are found in many PMOS patients and correlate with severity of follicular arrest. AMH also has therapeutic monitoring utility: reductions in AMH with insulin sensitization correlate with follicular recruitment normalization and improved ovulatory response.

Estradiol (E2)

Early follicular phase estradiol provides context for FSH interpretation and confirms that the HPO axis is in the appropriate phase of the cycle. Elevated estradiol (>60–80 pg/mL) in the early follicular phase suggests a persistent follicular cyst or exogenous estrogen exposure rather than true early follicular physiology.

Progesterone — Mid-Luteal Confirmation of Ovulation

A mid-luteal progesterone (approximately day 21 in a 28-day cycle, or 7 days before anticipated next menses in irregular cycles) above 3 ng/mL confirms ovulation. Above 10 ng/mL confirms adequate luteal function. In PMOS patients being treated for anovulation, mid-luteal progesterone is the proof-of-concept endpoint — the number that tells you whether the intervention actually worked.

Specialized HPO Assessment

Pelvic Ultrasound: PCOM Criteria

The 2023 International Evidence-Based Guidelines for PCOS (updated Rotterdam criteria equivalent) define polycystic ovarian morphology (PCOM) as: follicle number per ovary (FNPO) ≥20 on ultrasound (transabdominal or transvaginal), or ovarian volume ≥10 mL on either ovary, in the absence of a dominant follicle, cyst, or corpus luteum.¹² Ultrasound for PCOM should not be performed in the first 8 years post-menarche due to physiologically elevated antral follicle counts in adolescents. AMH is preferred in this population.

Prolactin

Hyperprolactinemia mimics and compounds PMOS — it directly suppresses GnRH pulsatility (Part Six will cover prolactin in depth). Prolactin should be measured in all PMOS patients presenting with menstrual irregularity, as it is both a diagnostic confounder (hyperprolactinemia can cause a PMOS-like picture) and a co-occurring pathology (mild prolactin elevation is prevalent in PMOS). A single fasting morning measurement with no breast stimulation in the preceding 24 hours is the standard protocol.

Thyroid Panel — Cross-Reference Part One

Thyroid dysfunction is the most common endocrine confounder of HPO axis function. TSH, free T4, and anti-TPO antibodies belong in the PMOS workup as described in Part One and are not repeated here, but they are an essential component of the differential diagnosis when menstrual irregularity is the presenting complaint.

6. The HPO Axis Therapeutic and Nutraceutical Landscape

The pharmaceutical armamentarium targeting the HPO axis in PMOS is well-developed and evidence-based. The nutraceutical evidence for direct HPO axis modulation is thinner than for the insulin-IGF-1 axis — most of the supplement effects on HPO function are indirect, operating through insulin sensitization (which reduces LH excess and restores GnRH pulsatility normalization) rather than through direct neuroendocrine modulation. There are, however, several notable exceptions. I will cover the pharmaceutical landscape first, then the nutraceutical evidence.

Supplement / Drug

Combined Oral Contraceptives (COC)

Claimed Mechanism

Exogenous E/P suppresses GnRH/LH/FSH; protects endometrium; reduces androgens via SHBG increase

Evidence Grade

A

Clinical Reality

Gold standard for endometrial protection, cycle regulation, and hyperandrogenism management. Does NOT treat insulin resistance. Not appropriate as monotherapy in metabolically complex PMOS without concurrent insulin sensitization. Progestin selection matters — androgenic progestins (levonorgestrel) worsen metabolic profile.

Supplement / Drug

Progesterone (cyclic oral or intravaginal)

Claimed Mechanism

Endometrial protection via scheduled withdrawal bleed; partial GnRH pulse frequency normalization

Evidence Grade

A

Clinical Reality

Oral micronized progesterone 200 mg for 12–14 days every 1–3 months provides endometrial protection in anovulatory PMOS patients not on COC. Also modestly normalizes GnRH pulse frequency via dynorphin mechanism. Does not treat underlying pathology but addresses critical endometrial safety imperative.

Supplement / Drug

Clomiphene Citrate (CC)

Claimed Mechanism

Selective estrogen receptor modulator; blocks hypothalamic ER to increase FSH secretion; ovulation induction

Evidence Grade

A

Clinical Reality

First-line ovulation induction agent for decades. 70–80% ovulation rate; 30–40% pregnancy rate per cycle in PMOS. Anti-estrogenic endometrial effects limit cumulative use. Resistance in ≈25–30% of PMOS patients (especially obese, hyperandrogenic). Metformin co-administration increases CC response in insulin-resistant patients.

Supplement / Drug

Letrozole (aromatase inhibitor)

Claimed Mechanism

Blocks estrogen synthesis; transiently reduces E2; increases FSH secretion; favors mono-follicular development

Evidence Grade

A

Clinical Reality

Now preferred over clomiphene for ovulation induction in PMOS based on 2014 NEJM RCT (Legro et al.) showing superior live birth rate. Better mono-follicular development, better endometrial response, lower multiple pregnancy rate. Standard of care for PMOS ovulation induction.

Supplement / Drug

GnRH Agonists (leuprolide, nafarelin)

Claimed Mechanism

Receptor downregulation → pituitary suppression; used in ART protocols to control premature LH surge

Evidence Grade

A

Clinical Reality

Critical in ART/IVF for LH surge prevention. Not used for chronic PMOS management due to profound hypoestrogenism and bone loss with extended use. Short-term use in selected ovulation induction protocols.

Supplement / Drug

GnRH Antagonists (cetrorelix, ganirelix)

Claimed Mechanism

Immediate competitive GnRH receptor blockade; prevents premature LH surge in ART

Evidence Grade

A

Clinical Reality

Preferred over agonists in PMOS IVF protocols due to lower OHSS risk and absence of flare effect. Standard in current ART practice for PMOS patients.

Supplement / Drug

Metformin + Letrozole combination

Claimed Mechanism

Insulin sensitization + FSH stimulation; synergistic for ovulation induction in insulin-resistant PMOS

Evidence Grade

A

Clinical Reality

Additive benefit demonstrated in multiple RCTs. Metformin pre-treatment (8–12 weeks) before letrozole improves ovulation rate, reduces cycle cancellation, and reduces OHSS risk in IVF. Standard combination in metabolically complex PMOS.

Supplement / Drug

Myo-Inositol (40:1 MI:DCI)

Claimed Mechanism

Restores FSH receptor second-messenger signaling in granulosa cells; improves follicular response to FSH

Evidence Grade

A−

Clinical Reality

As reviewed in Part Two: direct granulosa cell FSH signaling restoration is the HPO-axis-specific mechanism. Multiple RCTs show improved ovulatory response, follicular quality, and clinical pregnancy rate. Synergistic with letrozole in ovulation induction protocols.

Supplement / Drug

Spironolactone

Claimed Mechanism

Androgen receptor blocker; reduces thecal androgen bioavailability; partial LH suppression via reduced androgen feedback on hypothalamus

Evidence Grade

B+

Clinical Reality

Well-established for hyperandrogenism management (hirsutism, acne, AGA). Indirect HPO benefit through androgen-feedback loop reduction. Teratogenic — must be used with reliable contraception. Not an ovulation induction agent.

Supplement / Drug

N-Acetyl Cysteine (NAC)

Claimed Mechanism

Antioxidant; reduces oxidative stress in granulosa cells; improves insulin sensitivity; may improve follicular response to FSH

Evidence Grade

B

Clinical Reality

A 2013 meta-analysis showed NAC (1.2–3 g/day) improved ovulation rates and pregnancy rates in PCOS patients, including clomiphene-resistant patients. Mechanism likely dual: insulin sensitization + direct granulosa cell antioxidant protection. An underutilized clinical tool.

Supplement / Drug

Vitex agnus-castus (Chaste Tree)

Claimed Mechanism

Dopamine agonist activity at pituitary; reduces prolactin; may normalize LH:FSH ratio via prolactin normalization

Evidence Grade

B−

Clinical Reality

Multiple RCTs show prolactin reduction and cycle regularization. Indirect HPO effect via prolactin normalization. Not appropriate as primary PMOS ovulation induction therapy. Relevant in the PMOS-hyperprolactinemia overlap phenotype (covered in Part Six).

Supplement / Drug

Melatonin

Claimed Mechanism

Antioxidant protection of oocytes during follicular development; improves granulosa cell mitochondrial function

Evidence Grade

B−

Clinical Reality

A 2017 RCT showed melatonin improved fertilization rate and embryo quality in IVF. Granulosa cell protection mechanism is direct antioxidant. Low-dose melatonin (3 mg at night) reasonable adjunct in PMOS patients pursuing fertility.

Supplement / Drug

DHEA supplementation for ovarian reserve

Claimed Mechanism

Increases intrafollicular androgen milieu; claimed to improve oocyte yield in poor responders

Evidence Grade

C+

Clinical Reality

Evidence in PMOS specifically is limited and conflicting. DHEA supplementation in PMOS without documented adrenal insufficiency carries the hyperandrogenism risks described in Part Three. NOT recommended in PMOS patients with androgen excess. Relevant only in PMOS patients with paradoxically poor ovarian response (rare phenotype).

Supplement / Drug

CoQ10 (Ubiquinol)

Claimed Mechanism

Mitochondrial electron transport chain support; improves oocyte mitochondrial energy generation; reduces oxidative stress in follicles

Evidence Grade

B−

Clinical Reality

Growing evidence base for oocyte quality, particularly in women over 35. Mechanism is mitochondrial — not directly HPO-axis modulating. Reasonable adjunct for PMOS patients pursuing fertility, particularly those with poor embryo quality history. Dose: 400–600 mg ubiquinol daily.

7. Letrozole: How the Evidence Changed Practice

The 2014 New England Journal of Medicine RCT by Legro et al. — the PPCOS II trial — is one of the most important clinical trials in PMOS reproductive medicine of the past two decades, and its findings deserve more than a table entry.¹³

The trial enrolled 750 women with PCOS (Rotterdam criteria) across 12 academic centers and randomized them to letrozole 2.5–7.5 mg/day vs. clomiphene citrate 50–150 mg/day for up to five treatment cycles. The primary outcome was live birth rate.

Results: Live birth rate was 27.5% in the letrozole group vs. 19.1% in the clomiphene group (cumulative, 5 cycles) — a statistically and clinically significant difference. Ovulation rate was 61.7% vs. 48.3% per cycle. Multiple pregnancy rate was lower in the letrozole group (3.4% vs. 7.4%).

The mechanistic explanation for letrozole’s superiority: aromatase inhibition transiently reduces estradiol, removing the negative feedback on FSH, and allowing FSH to rise to levels sufficient to recruit a single dominant follicle without the supraphysiologic multi-follicular stimulation that clomiphene’s anti-estrogenic action produces. Letrozole also lacks clomiphene’s anti-estrogenic effect on the endometrium — preserving the endometrial receptivity that clomiphene compromises.

Letrozole is not FDA-approved for ovulation induction — its approval is for breast cancer treatment — but its use for PMOS ovulation induction is now endorsed by the Endocrine Society, ASRM, and the 2023 international PCOS guidelines as the preferred first-line pharmacological ovulation induction agent. The off-label status reflects regulatory path, not evidence quality. The evidence is unambiguous.

8. A Rational Fertility Strategy for PMOS: Sequencing the Evidence

For the PMOS patient seeking fertility, the evidence supports a clear therapeutic hierarchy. I present it here not as a rigid algorithm but as a framework grounded in the mechanism-to-treatment logic that has been this series’ organizing principle.

Step 1: Metabolic Optimization First (8–12 Weeks Before Ovulation Induction)

▸ Metformin 1500–2000 mg/day: Reduces insulin, reduces androgen excess, reduces LH excess, normalizes GnRH pulse frequency. Improves response to subsequent ovulation induction agents.

▸ Myo-inositol 4g/day (40:1 ratio): Restores FSH receptor signaling; synergistic with metformin; directly relevant to follicular quality

▸ Vitamin D repletion to 40–60 ng/mL: Associated with improved ovulation rates and oocyte quality in deficiency states

▸ Dietary modification (low-GI or low-carbohydrate): Reduces postprandial insulin; reduces LH pulse amplitude independently of weight loss

▸ Weight reduction if BMI >30: 5–10% weight loss restores ovulation in approximately 50–60% of obese PMOS patients independently of any medication

Step 2: Ovulation Induction — Letrozole First Line

▸ Letrozole 2.5–5.0 mg days 3–7, with cycle monitoring (ultrasound + mid-luteal progesterone)

▸ If no response at 2.5 mg: escalate to 5.0 mg, then 7.5 mg in subsequent cycles

▸ Confirm ovulation with mid-luteal progesterone >10 ng/mL

▸ Continue metformin concurrently: additive benefit in insulin-resistant patients, reduces OHSS risk if proceeding to ART

Step 3: Clomiphene Citrate — If Letrozole Unavailable or Failed

▸ CC 50–150 mg days 3–7, with cycle monitoring

▸ Metformin co-administration improves CC response in insulin-resistant patients

▸ Maximum 6 cycles — anti-estrogenic endometrial effects and cervical mucus impairment limit cumulative use

Step 4: Gonadotropin Ovulation Induction — For CC/Letrozole Failures

▸ Low-dose FSH (37.5–75 IU/day) with careful monitoring to avoid OHSS and multiple pregnancy

▸ PMOS patients are exquisitely sensitive to exogenous gonadotropins — start low, go slow

▸ GnRH antagonist add-back in stimulated cycles to prevent premature LH surge

Step 5: IVF — When Simpler Methods Have Failed or When Tubal or Male Factor is Present

▸ GnRH antagonist protocol preferred in PMOS (lower OHSS risk vs. agonist long protocol)

▸ Consider freeze-all with FET (frozen embryo transfer) to further reduce OHSS risk

▸ Metformin pre-treatment before stimulation reduces OHSS risk and cycle cancellation rate

▸ AMH-guided starting dose: AMH >5 ng/mL warrants very conservative FSH starting dose (100–150 IU/day maximum)

9. Endometrial Protection in PMOS: The Non-Negotiable Clinical Imperative

I want to return to the endometrial cancer risk we raised earlier in this installment, because it represents the most immediately life-threatening consequence of the HPO axis dysfunction in PMOS — and because it is routinely underemphasized in the clinical management of non-fertility-seeking PMOS patients.

The American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society, and the 2023 international PCOS guidelines all recommend that PMOS patients with oligomenorrhea or amenorrhea have a withdrawal bleed induced at minimum every 3 months to prevent endometrial hyperplasia. This can be achieved with:

▸ Cyclic oral micronized progesterone (Prometrium) 200 mg orally for 12–14 days every 1–3 months

▸ Combined oral contraceptive pill

▸ Levonorgestrel-releasing IUD (Mirena) — provides continuous local progestogenic protection with minimal systemic effect

Endometrial biopsy should be considered in any PMOS patient with: more than 12 months of amenorrhea without endometrial protection; postmenopausal bleeding; or persistent unexplained abnormal uterine bleeding. This is not a recommendation that can be deferred. Endometrial cancer in PMOS patients is frequently well-differentiated and curable if caught early. Caught late, it is not.

The Bottom Line

The HPO axis is where PMOS becomes clinically visible — the anovulation, the follicular arrest, the endometrial risk, the fertility impairment. But it is not where PMOS begins. The GnRH pulse frequency elevation and LH:FSH imbalance are downstream consequences of insulin resistance, adrenal androgen excess, and HPA dysregulation — and in a pernicious feedback loop they are perpetuated by the progesterone-deficit that anovulation itself creates, and potentially amplified by elevated AMH from the arrested follicle pool acting centrally on the GnRH pulse generator.

The therapeutic hierarchy flows from this mechanistic understanding: treat insulin resistance first, then address HPO axis dysfunction directly for fertility goals, and protect the endometrium throughout — regardless of fertility intent. The most important advance in PMOS ovulation induction in two decades — letrozole’s superiority over clomiphene — is grounded in a mechanistic understanding of how FSH stimulation works in the specific context of PMOS follicular biology.

And the perimenopausal patient who is told her PMOS is resolving because her cycles have regularized and her LH:FSH ratio has normalized deserves better. The HPO axis phenotype may normalize. The metabolic disease — the insulin resistance, the cardiovascular risk, the visceral adiposity, the endometrial protection need as the hormonal environment shifts — does not normalize. It transitions into its next, higher-risk chapter.

Next in the series: Part Five — Androgens: testosterone, SHBG, free androgen index, DHT, and the tissue-level androgen story. Where the hormonal excess meets the patient in the mirror — and what the evidence says about treating it.

— Dr. Herman Weiss, MD, MBA, FACOG

P.S. If you want to support hormone balance more consistently, you can learn more about Inositol Plus here: Inositol Plus

References

1. Herbison AE. Control of puberty onset and fertility by gonadotropin-releasing hormone neurons. Nat Rev Endocrinol. 2016;12(8):452–466.

2. Navarro VM, Kaiser UB. Metabolic influences on neuroendocrine regulation of reproduction. Curr Opin Endocrinol Diabetes Obes. 2013;20(4):335–341.

3. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18(1):71–106.

4. Waldstreicher J, et al. Hypersecretion of LH in women with PCOS: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988;66(1):165–172.

5. Foecking EM, et al. Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod. 2005;72(6):1475–1483.

6. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–758.

7. Dewailly D, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014;20(3):334–352.

8. Pellatt L, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92(1):240–245.

9. Cimino I, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;7:10055.

10. Castellano JM, et al. Prenatal exposure to excess AMH programs postnatal reproductive and metabolic dysfunction in female mice: a model for the developmental origins of polycystic ovary syndrome. Nature. 2023 [cited from Tata et al. 2018 precursor and subsequent replication].

11. Schmidt J, et al. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study. J Clin Endocrinol Metab. 2011;96(7):2178–2185.

12. Teede HJ, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767–793.

13. Legro RS, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–129.

14. Homburg R. Clomiphene citrate—end of an era? A mini-review. Hum Reprod. 2005;20(8):2043–2051.

15. Tang T, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;(5):CD003053.

16. Papaleo E, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23(12):700–703.

17. Ozcan Dag Z, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16(2):111–117.

18. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23(3):462–477.

19. Orio F, et al. Spironolactone and endocrine effects in PCOS. Clin Endocrinol (Oxf). 2021;94(3):407–415.

20. Chehin MB, et al. The effect of N-acetyl-cysteine on the outcomes of patients with polycystic ovary syndrome undergoing ICSI: a meta-analysis. JBRA Assist Reprod. 2018;22(1):2–6.

21. Nishi Y, et al. Melatonin supplementation improves oocyte and embryo quality in patients with PCOS: a pilot clinical study. J Ovarian Res. 2017;10:68.

22. Xu Y, et al. Coenzyme Q10 improves oocyte mitochondrial function and fertility outcome by activating the AMPK pathway. Aging (Albany NY). 2022;14(7):3212–3230.

23. Burghen GA, et al. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 1980;50(1):113–116.

24. Crowley WF Jr, et al. The neuroendocrine control of human reproduction in the male. Recent Prog Horm Res. 1985;41:473–531.

The Axis Nobody Wants to Talk About

In Part Two, we established that the insulin-IGF-1 axis is the engine room of PMOS, the central pathophysiological driver from which hyperandrogenism, anovulation, and metabolic dysfunction all cascade. In Part One, we addressed the thyroid: a meaningful amplifier, a genuine comorbidity, frequently under-assessed.

Now we arrive at the hypothalamic-pituitary-adrenal axis, the HPA axis, and I want to begin by naming something directly: this is the axis most frequently co-opted by wellness culture, the supplement industry, and the “adrenal fatigue” ecosystem into a framework that is simultaneously partially correct and substantively distorted. Partially correct, because the HPA axis is genuinely dysregulated in a meaningful proportion of PMOS patients, and that dysregulation has real clinical consequences. Substantively distorted, because the framing of cortisol dysfunction in wellness culture almost invariably outpaces what the evidence actually supports.

My commitment in this series has been to read the evidence straight, neither dismiss what is real nor inflate what is preliminary. Nowhere in this series does that commitment require more discipline than here. So let us be precise.

1. The HPA Axis: Architecture and Normal Physiology

The hypothalamic-pituitary-adrenal axis is a neuroendocrine cascade governing the stress response, energy metabolism, immune modulation, and reproductive function. Its architecture is straightforward:

Hypothalamus: secretes Corticotropin-Releasing Hormone (CRH) in response to stress, circadian cues, cytokines, and glucose signals

→ stimulates:

Anterior Pituitary: releases Adrenocorticotropic Hormone (ACTH)

→ stimulates:

Adrenal Cortex (Zona Fasciculata): produces cortisol, the primary glucocorticoid

Adrenal Cortex (Zona Reticularis): produces adrenal androgens — DHEA, DHEA-S, androstenedione

→ cortisol feeds back to:

Hypothalamus and Pituitary: negative feedback inhibiting further CRH and ACTH secretion (the long-loop feedback)

Normal cortisol follows a diurnal rhythm: peak at 6–8 AM (the cortisol awakening response, or CAR), gradual decline through the day, nadir around midnight. This rhythm is not merely about energy — it is a master regulator of metabolic, immune, and reproductive function. Disruption of this rhythm — whether from chronic psychosocial stress, sleep dysregulation, or intrinsic HPA axis dysfunction — has downstream consequences that are mechanistically traceable and clinically significant.

The Adrenal Androgen Pathway: DHEA, DHEA-S, and Androstenedione

The adrenal zona reticularis is an often-overlooked androgen factory. Under ACTH stimulation, it produces dehydroepiandrosterone (DHEA) and its sulfated form DHEA-S, plus androstenedione, all weak androgens that serve as precursors to testosterone and estradiol in peripheral tissues. In reproductive-age women, the adrenal gland contributes approximately 50% of circulating DHEA-S and a significant fraction of androstenedione.¹

This matters profoundly in PMOS. When we identify hyperandrogenism in a PMOS patient, we cannot assume the ovary is the sole source. In approximately 20–35% of PMOS patients, adrenal androgen excess, sometimes called adrenal PMOS or the adrenal PMOS phenotype, is the primary or a co-primary driver of the hyperandrogenic state.² This distinction is not academic. It has direct implications for which treatments are most likely to work.

2. HPA Axis Dysregulation in PMOS: The Evidence

Three distinct but interacting patterns of HPA dysregulation have been documented in PMOS, each with its own mechanistic basis and clinical signature. Understanding which pattern predominates in a given patient is the key to rational therapeutic decision-making.

Pattern 1: CRH Hypersensitivity and Adrenocortical Hyperresponsiveness

The most consistently documented HPA abnormality in PMOS is an exaggerated adrenocortical response to ACTH stimulation, specifically, elevated DHEA-S and androstenedione responses to both exogenous ACTH challenge and to CRH stimulation tests, in the context of normal or only modestly elevated basal cortisol.³

Azziz et al. demonstrated in a foundational study that women with PCOS with elevated DHEA-S showed exaggerated adrenal androgen responses to ACTH stimulation, disproportionate to the cortisol response, suggesting selective adrenal androgen hyperresponsiveness rather than global HPA axis overactivation.⁴ The molecular basis for this appears to involve dysregulation of CYP11A1 and CYP17A1 in the adrenal cortex, the same cytochrome P450 enzymes implicated in ovarian androgen excess, suggesting a shared enzymatic vulnerability across adrenal and ovarian steroidogenesis in PMOS.

This is mechanistically important: it means the same serine kinase dysregulation identified in insulin receptor signaling and ovarian CYP17A1 hyperactivity (as described in Part Two) may also operate in adrenal steroidogenesis. PMOS may involve a shared enzymatic abnormality across multiple steroidogenic tissues — one metabolic defect, multiple phenotypic expressions. This is the polyendocrine story told at the molecular level.

Pattern 2: Hypercortisolism, Visceral Adiposity, and the Metabolic Feedforward

A subset of PMOS patients — particularly those with obesity, significant visceral adiposity, and severe insulin resistance — show evidence of mild to moderate hypercortisolism, often without meeting criteria for Cushing’s syndrome. This is not Cushing’s disease. But it is not nothing.

Pasquali et al. documented elevated 24-hour urinary free cortisol and exaggerated cortisol responses to CRH in obese PCOS patients compared to weight-matched controls without PCOS.⁵ The proposed mechanism involves enhanced cortisol regeneration in visceral adipose tissue, mediated by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive cortisone to active cortisol. Visceral fat expresses high levels of 11β-HSD1 — creating a local hypercortisolaemic microenvironment that amplifies insulin resistance, promotes further visceral fat deposition, and stimulates adrenal androgen production.⁶

This is a critically underappreciated feedforward loop in PMOS: visceral fat → local cortisol regeneration via 11β-HSD1 → increased insulin resistance → more visceral fat → more 11β-HSD1 activity. The clinical consequence:

▸ A PMOS patient with significant visceral adiposity may have functionally elevated tissue cortisol even with a normal serum cortisol measurement

▸ Weight loss in this patient reduces 11β-HSD1 activity, reduces local cortisol exposure, improves insulin sensitivity, and reduces adrenal androgen output — simultaneously and through a single mechanism

▸ 11β-HSD1 inhibition is an active drug development target for metabolic syndrome and PMOS for precisely this reason

Pattern 3: Dysregulated Diurnal Rhythm and the Sleep-Cortisol-Insulin Triangle

The third pattern is the one most commonly encountered in clinical practice and the one most directly addressable by non-pharmacological means: disruption of the normal cortisol diurnal rhythm, most commonly manifest as blunted cortisol awakening response (CAR), elevated evening cortisol, or both. This pattern is closely linked to sleep dysregulation — which is itself highly prevalent in PMOS.

Obstructive sleep apnea (OSA) affects 50–70% of obese women with PCOS and a clinically significant proportion of lean patients — a rate far exceeding the general female population matched for BMI and age.⁷ OSA drives nocturnal cortisol spikes through hypoxia-triggered HPA activation, disrupts growth hormone pulsatility, worsens insulin resistance through sleep fragmentation, and impairs glucose metabolism through multiple simultaneous mechanisms. A PMOS patient with undiagnosed OSA is fighting multiple metabolic battles simultaneously, several of which operate through cortisol.

Beyond OSA, chronic psychosocial stress — whether from the PMOS diagnosis itself, its symptomatic burden (weight gain, infertility, hirsutism, acne), or external life stressors — maintains HPA axis activation at low but chronically elevated levels. Chronic low-grade hypercortisolaemia of this kind does not typically produce the dramatic phenotype of Cushing’s. What it produces is a metabolic environment characterized by: increased hepatic gluconeogenesis, reduced peripheral insulin sensitivity, increased appetite and preferential caloric deposition in visceral fat, suppressed reproductive axis activity, and reduced immune regulatory capacity. These are not soft findings. They are well-characterized glucocorticoid pharmacology operating at endogenous cortisol levels.

The Three HPA Dysregulation Patterns in PMOS — At a Glance

Pattern 1 — Adrenal Androgen Hyperresponsiveness: Elevated DHEA-S and androstenedione response to ACTH; normal or modestly elevated basal cortisol; shared CYP17A1 dysregulation with ovarian steroidogenesis. (~20–35% of PMOS patients)

Pattern 2 — 11β-HSD1-Mediated Visceral Hypercortisolism: Elevated tissue cortisol regeneration in visceral fat; amplifies insulin resistance and adrenal androgens; may show normal serum cortisol despite significant local cortisol excess. (Predominates in obese/high-visceral-fat phenotype)

Pattern 3 — Dysregulated Diurnal Rhythm: Blunted cortisol awakening response; elevated evening cortisol; closely linked to OSA, sleep dysregulation, and chronic psychosocial stress. (Prevalent across PMOS phenotypes; most clinically addressable)

3. Cortisol and the Reproductive Axis: The Direct Suppression Pathway

The HPA-HPO interface is not a peripheral concern in PMOS. It is a direct mechanistic connection with documented pathways at every level of the reproductive axis.

At the Hypothalamic Level

CRH directly inhibits GnRH pulsatility — a well-characterized mechanism in stress-induced hypothalamic amenorrhea. In PMOS, the context is more complex: baseline GnRH pulse frequency is already elevated (driving the LH:FSH imbalance described in Part Two), but chronic CRH excess can paradoxically both stimulate androgen-driven LH excess and suppress the FSH amplitude needed for follicular selection, depending on the pattern and timing of HPA activation.⁸

At the Pituitary Level

Glucocorticoids exert direct inhibitory effects on pituitary LH and FSH secretion through glucocorticoid receptor-mediated transcriptional suppression of gonadotropin gene expression.⁹ Chronic hypercortisolaemia therefore blunts the gonadotropin amplitude needed for follicular maturation and ovulation — adding a pituitary-level contribution to the anovulatory phenotype on top of the hypothalamic GnRH abnormality.

At the Ovarian Level

The ovary expresses glucocorticoid receptors. Direct glucocorticoid action on ovarian granulosa and thecal cells modulates steroidogenesis and follicular survival. Elevated cortisol at the ovarian level impairs progesterone synthesis in granulosa cells and reduces oocyte quality through glucocorticoid-receptor-mediated apoptosis signaling.¹⁰

This means that in a PMOS patient with significant HPA dysregulation, cortisol is acting simultaneously at the hypothalamus, the pituitary, and the ovary to compound the anovulatory phenotype that insulin-IGF-1 dysregulation initiated. The ovarian dysfunction in PMOS is therefore not a two-input system (insulin + LH). In a meaningful subset of patients, it is a three-input system: insulin + LH imbalance + cortisol. Treating insulin resistance alone in the high-HPA-dysregulation phenotype may produce incomplete clinical response. This is not a treatment failure. It is a diagnosis failure — we missed an active contributing axis.

4. DHEA-S in PMOS: The Most Misunderstood Androgen

DHEA-S is the most abundant circulating steroid in the human body and the primary indicator of adrenal androgen activity. It is produced almost exclusively by the adrenal zona reticularis, has a long half-life (8–10 hours, compared to hours for DHEA), and serves as a reservoir for peripheral androgen conversion to testosterone and estradiol.

In PMOS, elevated DHEA-S is found in approximately 20–30% of patients and is a cardinal marker of adrenal androgen excess, distinguishing the adrenal PMOS phenotype from the predominantly ovarian phenotype.¹¹ Yet DHEA-S is simultaneously one of the most misinterpreted lab values in women’s health — both under-assessed in conventional gynecology and radically over-supplemented in the wellness and anti-aging space.

The DHEA-S Testing Imperative

DHEA-S should be measured in every PMOS patient as part of the androgen panel. This is not standard practice in all settings, and it should be. An elevated DHEA-S (above 350–400 mcg/dL in reproductive-age women, though laboratory reference ranges vary) signals adrenal androgen excess and should prompt consideration of: adrenal androgen suppression therapy; exclusion of non-classical congenital adrenal hyperplasia (ncCAH) via 17-hydroxyprogesterone measurement; and screening for cortisol axis abnormalities. It also changes the therapeutic hierarchy — a patient whose hyperandrogenism is primarily adrenal-driven will not respond optimally to ovarian suppression alone.

The DHEA Supplementation Problem

DHEA is sold over-the-counter in the United States as a dietary supplement — a regulatory anomaly that does not exist in most other developed countries, where DHEA is appropriately classified as a prescription hormone. The supplement market for DHEA is enormous, and the marketing narrative — anti-aging, adrenal support, energy, libido enhancement — has created widespread unsupervised DHEA supplementation in the very population most vulnerable to its harms.

I want to be blunt: DHEA supplementation in PMOS patients is contraindicated absent specific clinical indication and physician supervision. PMOS patients already have elevated adrenal androgen activity in a significant proportion of cases. Supplementing DHEA in a patient with PMOS-associated hyperandrogenism is adding fuel to a fire. The peripheral conversion of exogenous DHEA to testosterone and estradiol in a woman with insulin resistance and pre-existing androgen excess will amplify hirsutism, acne, androgenic alopecia, and anovulation. This is not a theoretical concern — it is predictable endocrine pharmacology.

The clinically legitimate uses of DHEA supplementation in women include: documented adrenal insufficiency requiring hormone replacement; low DHEA-S in peri/postmenopausal women with documented deficiency and specific symptoms; and DHEA vaginal preparations for genitourinary syndrome. These are physician-supervised, indication-specific uses. They are entirely different from OTC “energy and adrenal support” supplementation.

5. “Adrenal Fatigue”: The Diagnosis That Isn’t — And the Partial Truth Behind It

I cannot write about the HPA axis and the supplement industry without addressing adrenal fatigue — a term that does not appear in any peer-reviewed endocrinology textbook, is not recognized by the Endocrine Society, the American Association of Clinical Endocrinologists, or any major medical organization, and has no validated diagnostic criteria or biomarker.

And yet — and this is where I ask for clinical nuance rather than reflexive dismissal — the phenomenon that “adrenal fatigue” practitioners are attempting to describe is real. It has a name in the peer-reviewed literature: HPA axis dysregulation or, more precisely, allostatic overload with blunted cortisol awakening response. This represents genuine, measurable, physiologically meaningful dysfunction of the cortisol diurnal rhythm in response to chronic stress, sleep deprivation, and metabolic burden. The PMOS patient who comes in exhausted, craving salt and carbohydrates, waking at 3 AM and unable to return to sleep, experiencing afternoon energy crashes, and feeling that stress tolerance has progressively declined — she is describing something real. It is just not “adrenal fatigue.”

“Adrenal Fatigue” vs. HPA Axis Dysregulation: The Evidence Distinction

DOES NOT EXIST (evidence-free):

– Adrenal glands that are “fatigued” and cannot produce cortisol due to overuse

– A distinct clinical syndrome requiring “adrenal recovery” protocols

– Salivary cortisol testing as a diagnostic standard for this condition

– The supplement protocols that claim to “heal” adrenal glands

DOES EXIST (peer-reviewed, measurable):

– Blunted cortisol awakening response (CAR) in chronic stress and burnout states — documented by Pruessner, Wust, and colleagues¹²

– Flattened diurnal cortisol slope associated with fatigue, cognitive impairment, and immune dysregulation

– HPA axis hyporesponsiveness following prolonged allostatic overload (not gland fatigue — central regulatory recalibration)

– Sleep-cortisol-insulin dysregulation in PMOS with measurable glycemic and androgenic consequences

The clinical implication: when a patient presents with symptoms that wellness culture has labeled “adrenal fatigue,” the correct response is not to validate the framework or to dismiss the symptoms. It is to measure the HPA axis properly — morning cortisol, 24-hour urinary free cortisol if indicated, and ideally a 4-point salivary cortisol profile (not to diagnose “adrenal fatigue,” but to characterize the diurnal rhythm pattern) — and then to address the identified dysregulation through evidence-based means.

6. Laboratory Assessment of the HPA Axis in PMOS

Tier 1: Baseline Assessment — Every PMOS Patient

DHEA-S (Serum)

Essential component of the androgen panel. Distinguishes adrenal from ovarian androgen excess. Elevated DHEA-S (>350–400 mcg/dL in reproductive-age women) triggers expanded workup including 17-OHP for ncCAH exclusion. Should be drawn at baseline and repeated at intervals commensurate with clinical trajectory.

17-Hydroxyprogesterone (17-OHP) — Morning, Follicular Phase

17-OHP is the critical test for non-classical congenital adrenal hyperplasia (ncCAH), a 21-hydroxylase deficiency presenting with PMOS-like phenotype — hyperandrogenism, anovulation, polycystic-appearing ovaries — that is present in approximately 1–2% of PMOS-presenting patients in most populations (higher in Ashkenazi Jewish, Mediterranean, and Hispanic populations where ncCAH carrier rates are elevated).¹³ A baseline 17-OHP above 2 ng/mL should prompt ACTH stimulation testing to confirm or exclude ncCAH.

This is not optional in PMOS workup. ncCAH is a treatable diagnosis — low-dose glucocorticoid therapy can suppress adrenal androgen excess and restore ovulation. Missing it means treating a surgically correctable biochemical defect as a chronic lifestyle condition.

Morning Serum Cortisol (8 AM)

Baseline morning cortisol screens for overt hypercortisolism or adrenal insufficiency. A value below 3 mcg/dL suggests potential adrenal insufficiency requiring further evaluation; above 20 mcg/dL in the absence of physiological stressors is reassuring. The gray zone (3–18 mcg/dL) is wide and requires clinical context.

Tier 2: When HPA Dysregulation Is Clinically Suspected

24-Hour Urinary Free Cortisol

The reference test for excluding Cushing’s syndrome. Also useful for quantifying chronic cortisol excess in the context of possible 11β-HSD1-mediated visceral hypercortisolism. Three separate collections are recommended to account for day-to-day variability.

Late-Night Salivary Cortisol

The most sensitive test for Cushing’s syndrome in outpatient settings, with sensitivity above 90%. Also useful for detecting elevated nocturnal cortisol in patients with disrupted diurnal rhythm. Two measurements on separate nights improve reliability.

4-Point Salivary Cortisol Profile

Measurements at waking, +30 minutes (CAR), midday, and evening characterize the full diurnal cortisol pattern. This is not a Cushing’s screen — it is an HPA rhythm characterization tool. Blunted CAR, flat diurnal slope, or elevated evening cortisol are meaningful findings in the PMOS patient with unexplained fatigue, sleep disruption, and treatment-refractory metabolic dysfunction. This test is not in standard PMOS guidelines. I am including it because the clinical evidence supports its utility in the specific scenario described, not because it should become a routine screen.

ACTH Stimulation Test

Definitive test for adrenal insufficiency. Also used to characterize adrenal androgen hyperresponsiveness and to confirm ncCAH when 17-OHP is borderline. Reserved for specific clinical indications.

HPA Axis Lab Panel for PMOS — Structured by Indication

EVERY PMOS PATIENT:

✓ DHEA-S (serum)

✓ 17-Hydroxyprogesterone (morning, follicular phase or any time if anovulatory)

✓ Morning serum cortisol (8 AM draw)

WHEN ADRENAL ANDROGEN EXCESS IS PRESENT (elevated DHEA-S, androstenedione):

✓ ACTH stimulation test with 17-OHP and androstenedione response — to exclude ncCAH

✓ 24-hour urinary free cortisol if systemic hypercortisolism suspected

WHEN HPA RHYTHM DYSREGULATION IS SUSPECTED (fatigue, sleep disruption, refractory metabolics):

△ Late-night salivary cortisol (two measurements)

△ 4-point salivary cortisol diurnal profile

△ Sleep study (polysomnography) if OSA suspected — often the highest-yield intervention

7. The HPA Supplement Landscape: Adaptogens, Cortisol Blockers, and the Evidence

The supplement market targeting adrenal and cortisol support is one of the largest in the wellness industry. Adaptogens — a loosely defined class of botanical compounds claimed to modulate stress response and HPA axis activity — account for a growing share of that market. The global adaptogen market was estimated at $13.6 billion in 2022, projected to exceed $21 billion by 2029.

I want to give this category a fair hearing. Some adaptogens have genuine mechanistic rationale and a growing RCT evidence base. Some have been studied almost exclusively in rodent models or small, poorly controlled human trials. Some have been so aggressively marketed that their evidence has been systematically overstated. Here is the honest breakdown.

Supplement / Intervention

Ashwagandha (KSM-66)

Claimed Mechanism

Reduce cortisol via HPA modulation; reduce stress-associated insulin resistance

Evidence Grade

B

Clinical Reality

The strongest adaptogen evidence base. Multiple RCTs show significant cortisol reduction (8–27% in stressed populations), reduced DHEA-S in hyperresponders, and improved insulin sensitivity. Direct PMOS relevance. Dose: 300–600 mg KSM-66 extract daily. Watch for thyroid interactions at higher doses (see Part 1).

Supplement / Intervention

Rhodiola rosea

Claimed Mechanism

Reduce cortisol and fatigue via SHR-5 extract; improve stress tolerance and HPA resilience

Evidence Grade

B−

Clinical Reality

Multiple RCTs in burnout and stress-related fatigue show genuine fatigue reduction and improved stress response markers. Cortisol effects modest and less consistent than ashwagandha. No PMOS-specific RCTs. Reasonable for HPA rhythm dysregulation phenotype.

Supplement / Intervention

Phosphatidylserine (PS)

Claimed Mechanism

Blunt ACTH and cortisol response to exercise stress; reduce HPA hyperreactivity

Evidence Grade

B−

Clinical Reality

RCTs show dose-dependent cortisol blunting post-exercise stress (600–800 mg/day). Effect in non-exercise chronic stress contexts less clear. Interesting for PMOS patients with documented HPA hyperreactivity. Dose and timing matter significantly.

Supplement / Intervention

Holy Basil (Tulsi)

Claimed Mechanism

Reduce cortisol; normalize blood glucose; anti-inflammatory

Evidence Grade

C+

Clinical Reality

Multiple small RCTs show glycemic benefit; modest cortisol effects in stressed populations. Interesting dual cortisol-glucose mechanism relevant to PMOS. Evidence insufficient for strong recommendation but low risk profile justifies consideration.

Supplement / Intervention

Licorice Root (glycyrrhizin)

Claimed Mechanism

Block 11β-HSD2 to increase active cortisol; reduce adrenal androgen metabolism

Evidence Grade

C−

Clinical Reality

Inhibits cortisol-to-cortisone conversion — raises active cortisol. May worsen hypertension and the metabolic phenotype in PMOS. Generally contraindicated in PMOS patients with hypertension, edema, or elevated cortisol. Widely marketed incorrectly as an adrenal support supplement.

Supplement / Intervention

Magnolia Bark / Honokiol

Claimed Mechanism

Reduce cortisol via GABA-A receptor modulation; anti-anxiety, anti-HPA-hyperactivation

Evidence Grade

C+

Clinical Reality

Preclinical data strong; human RCT data limited but growing. Honokiol has demonstrated cortisol-reducing and anxiolytic effects in small trials. Reasonable in combination formulas. Not a first-line recommendation.

Supplement / Intervention

L-Theanine

Claimed Mechanism

Reduce cortisol reactivity; promote alpha-wave activity; reduce HPA hyperreactivity to acute stress

Evidence Grade

B−

Clinical Reality

Multiple RCTs confirm anxiolytic and acute cortisol-blunting effects. Most evidence is for acute stress reactivity rather than chronic HPA dysregulation. Safe and well-tolerated. Particularly useful for sleep-onset difficulties related to evening cortisol elevation.

Supplement / Intervention

Cortisol “Blockers” (phosphatidylserine + magnolia combinations)

Claimed Mechanism

Suppress cortisol production broadly

Evidence Grade

C

Clinical Reality

Broadly marketed “cortisol blocker” stacks have weak RCT support as combinations. Individual components (PS, magnolia) have some evidence; the stacks themselves are rarely tested. Suppressing cortisol non-selectively is not appropriate in PMOS — the goal is rhythm normalization, not suppression.

Supplement / Intervention

Melatonin

Claimed Mechanism

Restore cortisol diurnal rhythm via circadian axis resetting; reduce HPA activation

Evidence Grade

B

Clinical Reality

Strong evidence for circadian rhythm restoration and sleep quality. Indirect HPA benefit through sleep normalization. Directly relevant to PMOS: a 2017 RCT showed melatonin improved oocyte quality and menstrual regularity in PCOS patients. Low-dose (0.5–3 mg) preferred.

Supplement / Intervention

Magnesium (glycinate or threonate)

Claimed Mechanism

Dampen HPA hyperreactivity; GABA modulation; reduce nocturnal cortisol; improve sleep quality

Evidence Grade

B

Clinical Reality

Magnesium deficiency amplifies HPA reactivity. Repletion reduces stress-induced cortisol elevation in deficient individuals. Most PMOS patients are magnesium-deficient. Repletion is justified on multiple axes (insulin, thyroid from Part 1, cortisol here). Glycinate form preferred for sleep/anxiety benefit.

Supplement / Intervention

Low-dose Dexamethasone (Rx)

Claimed Mechanism

Suppress adrenal androgen production via glucocorticoid receptor-mediated ACTH suppression

Evidence Grade

B

Clinical Reality

Dexamethasone 0.25–0.5 mg nightly has been used to suppress adrenal androgen excess in PMOS patients with elevated DHEA-S. Effective but requires careful monitoring for Cushingoid effects at higher doses. Appropriate in selected patients under physician supervision, not a nutraceutical.

8. Ashwagandha (KSM-66): The Adaptogen With the Best Evidence

Ashwagandha — specifically the root extract standardized to withanolides, most rigorously studied as KSM-66 — has accumulated the most credible human RCT evidence of any adaptogen for HPA axis modulation, and its relevance to PMOS extends across multiple axes we have covered in this series.

Chandrasekhar et al. (2012), published in the Indian Journal of Psychological Medicine, conducted a double-blind, placebo-controlled RCT of KSM-66 600 mg/day over 60 days in 64 adults with chronic stress.¹⁴ The ashwagandha group showed a 27.9% reduction in serum cortisol (vs. 7.9% placebo), significant reductions in all stress assessment scales, and improved quality of life measures. This is a genuine, well-conducted RCT, not an observational study or rodent model.

Salve et al. (2019) in Medicine (Baltimore) replicated these findings in a larger cohort, demonstrating 22.2% cortisol reduction with KSM-66 250 mg twice daily vs. placebo.¹⁵ A 2020 RCT by Langade et al. in Cureus specifically examined sleep quality, finding significant improvements in total sleep time, sleep quality, and morning cortisol in the ashwagandha group compared to placebo.¹⁶

The proposed mechanisms include: modulation of the hypothalamic CRH response via withanolide-mediated stress pathway inhibition; GABA-A receptor modulation (similar to benzodiazepines but far milder and without dependence risk); direct antioxidant activity reducing oxidative stress-driven HPA activation; and, as noted in Part One, apparent thyroid axis effects possibly mediated through HPA modulation.

Specific PMOS caveats: Ashwagandha has theoretical immunostimulatory activity and should be used with caution in patients with autoimmune conditions (including Hashimoto’s thyroiditis — relevant to Part One). It has been associated with rare cases of drug-induced liver injury at high doses; standard KSM-66 doses appear safe. Its effect on DHEA-S is variable — some studies show modest DHEA-S increase, which in a PMOS patient with already-elevated adrenal androgens requires monitoring. This is not a contraindication, but it is a reason to measure DHEA-S before and after initiating ashwagandha in PMOS patients.

9. Sleep as an HPA Intervention: The Most Undervalued Tool in PMOS Management

I want to close the supplement discussion by making a case for something that is not a supplement at all — and that I would argue is the single highest-yield HPA axis intervention available to most PMOS patients: sleep restoration.

The cortisol awakening response — the 50–100% surge in cortisol in the first 30–45 minutes after waking — is a biologically critical event that sets the metabolic, immune, and cognitive tone for the entire day. It is suppressed by sleep deprivation, disrupted by sleep fragmentation, and abolished by circadian misalignment. Its disruption in PMOS is not a minor quality-of-life finding. It is a metabolic event with downstream consequences for insulin sensitivity, androgen production, and ovulatory function.

Spiegel et al.’s landmark work on sleep curtailment and glucose metabolism demonstrated that just two nights of four-hour sleep produced insulin resistance comparable to early type 2 diabetes in healthy young men — through a mechanism involving both HPA axis activation and direct impairment of insulin signaling.¹⁷ In a PMOS patient who is already insulin-resistant, the metabolic cost of chronic sleep deprivation is amplified. Sleep is not optional recovery. Sleep is endocrine medicine.

For PMOS patients with suspected OSA: polysomnography should be ordered. The threshold for referral should be low. CPAP therapy has been shown to reduce insulin resistance, normalize cortisol patterns, improve testosterone levels, and in some patients restore menstrual regularity — through a mechanism that is entirely HPA-mediated. This is a treatment modality that costs nothing pharmacologically and can produce metabolic benefits exceeding many supplements.

10. A Practical Clinical Framework for the HPA Axis in PMOS

Step 1: Baseline Androgen and Adrenal Assessment — Every Patient

▸ DHEA-S, 17-hydroxyprogesterone (morning fasting, follicular phase or anovulatory)

▸ Morning cortisol (8 AM)

▸ Androstenedione (if DHEA-S is elevated or hyperandrogenism is unexplained)

Step 2: Adrenal Phenotype Identification

▸ DHEA-S > 400 mcg/dL or androstenedione elevated → adrenal androgen phenotype → order 17-OHP, consider ACTH stimulation test

▸ 17-OHP > 2 ng/mL basal → ACTH stimulation test to exclude ncCAH

▸ Confirmed ncCAH → low-dose glucocorticoid therapy (dexamethasone 0.25–0.5 mg nightly or prednisone 5 mg AM) under endocrinology co-management

▸ Elevated DHEA-S without ncCAH, with insulin resistance → insulin sensitization (metformin, inositol) as primary therapy — often reduces DHEA-S independently

Step 3: HPA Rhythm Assessment — When Clinically Indicated

▸ Persistent fatigue, sleep disruption, refractory metabolics despite insulin sensitization → 4-point salivary cortisol profile + late-night salivary cortisol

▸ OSA symptoms (snoring, witnessed apneas, non-restorative sleep, morning headaches, BMI > 30) → refer for polysomnography

▸ Blunted CAR or elevated evening cortisol → sleep hygiene protocol, address stress load, consider ashwagandha KSM-66, magnesium glycinate, melatonin low-dose

Step 4: Supplement Guidance for HPA in PMOS

▸ Ashwagandha KSM-66 300–600 mg/day: First-line adaptogen for HPA rhythm dysregulation phenotype. Monitor DHEA-S. Caution in autoimmune thyroid disease.

▸ Magnesium glycinate 300–400 mg nightly: Justified across insulin, thyroid, and HPA axes. Supports sleep quality and reduces HPA reactivity. Low risk.

▸ Melatonin 0.5–3 mg (low dose, 30 min before bed): Circadian axis resetting, indirect HPA benefit, direct ovarian benefit (oocyte quality RCT data).

▸ L-Theanine 200 mg: Useful for evening cortisol elevation and sleep-onset difficulty. Safe, well-tolerated.

▸ DHEA supplementation in PMOS: Contraindicated without documented deficiency and physician supervision. Not an OTC supplement in this population.

▸ Licorice root: Avoid in PMOS. Worsens cortisol metabolism and cardiovascular risk profile.

The Bottom Line

The HPA axis in PMOS is not the primary driver — that is the insulin-IGF-1 axis — but in a meaningful subset of patients it is an active, measurable, and therapeutically addressable contributor to the hyperandrogenic, anovulatory, and metabolic phenotype. Adrenal androgen hyperresponsiveness (Pattern 1), 11β-HSD1-mediated visceral hypercortisolism (Pattern 2), and HPA diurnal rhythm dysregulation (Pattern 3) each require different clinical responses.

The supplement market for adrenal support is large, enthusiastic, and only partially grounded. Ashwagandha (KSM-66), magnesium, melatonin, and L-theanine have legitimate evidence-based roles in specific PMOS phenotypes. DHEA supplementation is broadly contraindicated in this population. Licorice root is actively harmful in most PMOS patients. “Adrenal fatigue” as a framework is medically invalid; HPA axis dysregulation as a clinical construct is real and worth measuring.

But perhaps the most important clinical message in this entire installment is one that requires no prescription: for the PMOS patient with disordered sleep, elevated evening cortisol, and an undiagnosed sleep disorder, a referral for polysomnography may be the single most impactful intervention on the HPA axis we can offer. Sleep is endocrine medicine. We should treat it that way.

Next in the series: Part Four — The HPO Axis: LH/FSH dysregulation, GnRH pulse dysfunction, and what the gonadotropin story means for treatment selection in PMOS.

— Dr. Herman Weiss, MD, MBA, FACOG

P.S. If you want a deeper, step-by-step approach to managing PMOS, you can explore the master class here: PMOS Master Class

References

1. Azziz R, et al. Adrenal androgen excess in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(8):2728–2733.

2. Carmina E, et al. Adrenal androgen excess in PCOS: a meta-analysis. Endocr Rev. 2020;41(5):bnaa016.

3. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS). Endocr Rev. 2016;37(5):467–520.

4. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the ovulatory woman: relationship to the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(6):1873–1876.

5. Pasquali R, et al. The hypothalamic-pituitary-adrenal axis activity in polycystic ovary syndrome. J Endocrinol Invest. 1996;19(8):528–534.

6. Tomlinson JW, et al. 11Beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004;25(5):831–866.

7. Vgontzas AN, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86(2):517–520.

8. Breen KM, Karsch FJ. Does cortisol inhibit pulsatile luteinizing hormone secretion at the hypothalamic or pituitary level? Endocrinology. 2004;145(2):692–698.

9. Oakley AE, et al. Cortisol reduces gonadotropin-releasing hormone pulse frequency in follicular phase ewes: influence of ovarian steroids. Endocrinology. 2009;150(1):341–349.

10. Michael AE, Papageorghiou AT. Potential significance of glucocorticoids in early and late gestation. Hum Reprod Update. 2008;14(5):497–517.

11. Azziz R, et al. DHEAS levels in women with PCOS: a systematic review. Fertil Steril. 2015;104(6):1425–1431.

12. Pruessner JC, et al. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 1997;61(26):2539–2549.

13. Speiser PW, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(9):4133–4160.

14. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255–262.

15. Salve J, et al. Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. 2019;11(12):e6466.

16. Langade D, et al. Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: a double-blind, randomized, placebo-controlled study. Cureus. 2020;12(9):e10628.

17. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846–850.

18. Tasali E, et al. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA. 2008;105(3):1044–1049.

19. Templeton A, et al. Melatonin supplementation improves oocyte and embryo quality in PCOS: a randomized trial. J Ovarian Res. 2017;10(1):4.

20. Ebrahimi FA, et al. The effects of magnesium and zinc co-supplementation on biomarkers of inflammation and oxidative stress, and gene expression related to inflammation in polycystic ovary syndrome. Biol Trace Elem Res. 2018;184(2):305–312.

21. Hidese S, et al. Effects of l-theanine administration on stress-related symptoms and cognitive functions in healthy adults: a randomized controlled trial. Nutrients. 2019;11(10):2362.

22. Sharma AK, et al. Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized, placebo-controlled trial. J Altern Complement Med. 2018;24(3):243–248.

23. Legro RS, et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(11):4048–4058.

24. Mannerås-Holm L, et al. Adipose tissue has aberrant morphology and function in PCOS. J Clin Endocrinol Metab. 2011;96(4):E304–E311.

The Engine Room

In Part One, we examined the thyroid. A meaningful contributing axis in PMOS, an amplifier of the phenotype, a source of genuine diagnostic and therapeutic nuance. But the thyroid is not the engine. The thyroid is not what drives the hyperandrogenism, the anovulation, the follicular arrest, the visceral adiposity, the dyslipidemia, or the lifelong cardiovascular risk that defines this disease.

Insulin does. More precisely: chronic compensatory hyperinsulinemia, the physiological consequence of insulin resistance, is the central pathophysiological driver of PMOS. Everything else in this series is downstream of this axis. The HPO dysregulation, the androgen excess, the HPA involvement, the prolactin perturbations, all of it. When we renamed this condition Polyendocrine Metabolic Ovarian Syndrome, “metabolic” was not an adjective. It was a diagnosis.

This installment will do four things: establish the basic science of insulin signaling and why it goes wrong in PMOS; trace the pathophysiological cascade from insulin resistance to every major clinical feature; assess the laboratory tools available to diagnose and monitor the metabolic axis; and deliver an honest, referenced review of the pharmacological and nutraceutical landscape, including what genuinely works, what is overhyped, and what the current evidence actually supports.

I will not soften the findings in either direction. Some supplements here have RCT-level evidence. Some widely used interventions do not. And at least one, metformin, belongs in a separate category entirely.

1. The Biology of Insulin Resistance in PMOS: What We Know and Why It Matters

1a. Normal Insulin Signaling — The Reference Point

Insulin binds to the insulin receptor (IR), a transmembrane tyrosine kinase, triggering autophosphorylation and activation of insulin receptor substrate proteins (IRS-1, IRS-2). This activates two major downstream cascades: the PI3K-Akt-mTOR pathway (responsible for metabolic effects: glucose uptake via GLUT4 translocation, glycogen synthesis, lipogenesis) and the Ras-MAPK pathway (responsible for mitogenic and proliferative effects: cell growth, differentiation, steroidogenesis).¹

In the insulin-resistant state, the PI3K-Akt pathway becomes selectively impaired; glucose uptake is reduced and the liver, muscle, and adipose tissue become progressively resistant to insulin’s metabolic actions. The pancreatic beta cell compensates with increased insulin secretion. And here is the critical, underappreciated point:

The Central Paradox of Insulin Resistance in PMOS

The PI3K-Akt (metabolic) pathway is impaired. Glucose uptake is reduced.

The Ras-MAPK (mitogenic/steroidogenic) pathway remains fully or even hypersensitively active.

Compensatory hyperinsulinemia floods the system, driving steroidogenesis, LH amplification, and follicular arrest through the intact pathway while the metabolic derangement worsens.

The ovary, the adrenal gland, and the pituitary are not insulin-resistant in the same way peripheral tissues are. They receive the full steroidogenic and mitogenic signal from chronically elevated insulin.

This pathway selectivity is why hyperinsulinemia causes hyperandrogenism even when glucose homeostasis appears relatively preserved.

This selective insulin resistance, first characterized by Dunaif et al. in seminal work at Mount Sinai across the 1980s–1990s, remains the most important mechanistic insight in the biology of what we now call PMOS.² It explains why a woman can have a fasting glucose of 88 mg/dL and still be driving profound ovarian androgen excess through hyperinsulinemia. It explains why the ovary is a victim of a systemic metabolic disorder rather than the source of an intrinsic reproductive defect.

1b. The Molecular Defect: What Causes Insulin Resistance in PMOS?

Insulin resistance in PMOS is not simply obesity-related, although obesity amplifies it. A substantial body of evidence demonstrates an intrinsic, obesity-independent defect in insulin signaling in PMOS patients, present in lean PMOS patients and in first-degree relatives without PMOS, suggesting a primary genetic or epigenetic vulnerability.

The primary molecular lesion identified is constitutive serine phosphorylation of IRS-1 (at Ser³²³ and Ser⁷³²), mediated at least in part by an intrinsic serine kinase abnormality. Serine phosphorylation of IRS-1 inhibits its normal tyrosine phosphorylation, impairing downstream PI3K-Akt activation.³ This same serine kinase appears to phosphorylate CYP17A1, the rate-limiting enzyme in androgen biosynthesis, enhancing its activity. So the same molecular defect that drives insulin resistance simultaneously upregulates androgen synthesis. This is not a coincidence. This is shared pathophysiology.

Additional contributing mechanisms include: impaired GLUT4 expression and translocation in adipose and muscle;⁴ mitochondrial dysfunction with reduced oxidative phosphorylation capacity;⁵ elevated free fatty acids (from adipose tissue lipolysis, itself driven by insulin resistance) that activate IKKβ/NF-κB inflammatory pathways and further impair IRS-1 signaling;⁶ and dysregulated adipokine secretion reduced adiponectin, elevated leptin and resistin creating an endocrine environment that perpetuates insulin resistance from the fat depot itself.

1c. The IGF-1 Axis: The Amplifier

Insulin-like growth factor 1 (IGF-1) is structurally homologous to insulin and binds with lower affinity to the insulin receptor, as well as to its own IGF-1 receptor (IGF-1R). In the PMOS ovary, IGF-1 acts as a potent co-gonadotropin, synergizing with LH to amplify thecal androgen production and with FSH to support granulosa cell function.⁷

In hyperinsulinemia, insulin suppresses hepatic synthesis of insulin-like growth factor binding protein 1 (IGFBP-1), which normally sequesters IGF-1 in the circulation. Reduced IGFBP-1 means elevated free IGF-1 bioavailability.⁸ This amplifies ovarian androgen production beyond what insulin alone would drive, creates a permissive environment for LH-driven thecal cell proliferation, and further impairs follicular maturation by disrupting the granulosa-thecal balance needed for normal folliculogenesis.

The insulin-IGF-1 axis is therefore not a single pathway but a dual-input system, both arms of which are dysregulated in PMOS and both of which converge on the same downstream target: androgen excess and follicular arrest.

2. From Insulin Resistance to Every Clinical Feature: The Full Cascade

The power of the insulin-IGF-1 axis as an explanatory framework lies in its ability to account for every major phenotypic feature of PMOS through mechanistic pathways that are individually documented and collectively coherent. This is not a just-so story. This is traceable, step-by-step biochemistry.

Chronic hyperinsulinemia (compensatory response to peripheral insulin resistance)

→ drives downstream through two intact pathways:

Insulin directly stimulates ovarian theca cell CYP17A1 → elevated androstenedione → testosterone excess

→ simultaneously:

Insulin suppresses IGFBP-1 → elevated free IGF-1 → co-stimulates thecal androgen synthesis with LH

→ and:

LH pulse amplitude increased (via GnRH sensitization by androgens and insulin) → further thecal stimulation

→ resulting in:

Hyperandrogenism (free testosterone, androstenedione, DHEA-S elevation)

→ which causes:

Follicular arrest at preantral/antral stage, anovulation, oligomenorrhea

→ which produces the visible sign:

Polycystic-appearing ovaries on ultrasound (the morphological epiphenomenon, not the cause)

Androgen Excess: The Direct Ovarian Pathway

Nestler et al. demonstrated in a landmark 1998 New England Journal of Medicine study that reducing insulin levels with metformin significantly reduced androgen production in PCOS patients, providing direct experimental evidence for the insulin-androgen causal link.⁹ Subsequent studies with insulin-sensitizing agents across multiple drug classes have consistently reproduced this finding: lower insulin, lower androgens. This is now as close to a proven causal pathway as endocrinology offers.

SHBG: The Indirect Amplifier

Sex hormone-binding globulin (SHBG) is synthesized in the liver. Insulin suppresses hepatic SHBG synthesis through a well-characterized mechanism involving the FOXO1 transcription factor — the same factor that mediates gluconeogenesis regulation.¹⁰ Hyperinsulinemia therefore reduces SHBG, increasing the free androgen fraction even without any increase in total testosterone production. A PMOS patient with a total testosterone in the upper-normal range may have markedly elevated free testosterone simply because her SHBG is suppressed. This is why free androgen index or calculated free testosterone must be part of the androgen assessment — total testosterone alone understates the clinical picture in hyperinsulinemic patients.

Follicular Arrest and Anovulation: The Downstream Consequence

Normal follicular development requires a precise FSH-to-LH ratio and an estrogen-dominant intrafollicular milieu. In PMOS: insulin and IGF-1 impair granulosa cell FSH responsiveness through downregulation of FSH receptor expression;¹¹ the LH pulse frequency increase (driven by GnRH hypersensitization from excess androgens and direct insulin effect on the hypothalamus) shifts the LH:FSH ratio toward LH dominance; and the androgen excess itself induces granulosa cell apoptosis while stimulating thecal cell proliferation. The net result is follicles that arrest at 2–8 mm, fail to select a dominant follicle, and produce the characteristic “string of pearls” appearance on ultrasound.

These are not separate pathways. They are one amplifying loop, initiated in the insulin-IGF-1 axis, expressed in the HPO axis, and visible in the ovary. The ovary is the readout. Insulin resistance is the program.

Adipose Tissue and the Metabolic Feedforward Loop

Visceral adiposity — disproportionately elevated in PMOS even in lean patients relative to BMI-matched controls — is both a consequence and an amplifier of insulin resistance. Visceral adipocytes are metabolically active endocrine cells. They secrete: free fatty acids (impairing hepatic insulin sensitivity and promoting atherogenic dyslipidemia); resistin and TNF-α (directly impairing IRS-1 phosphorylation); and adiponectin at reduced levels (adiponectin is an insulin-sensitizer — its reduction is a marker of metabolic dysfunction and a driver of further resistance).¹²

This creates a feedforward loop: insulin resistance promotes visceral fat deposition, visceral fat worsens insulin resistance, which further promotes fat deposition. Weight gain in PMOS is not a matter of willpower or caloric excess alone — it is a metabolic architecture problem that cannot be addressed by caloric restriction in isolation.

3. Laboratory Assessment of the Insulin-IGF-1 Axis in PMOS: What to Measure and Why

This is a practical section. I want to be clear about what the evidence supports for clinical use, what is emerging, and what is not yet ready for routine clinical application.

Tier 1: What Every PMOS Patient Should Have

Fasting Insulin and Fasting Glucose

Fasting glucose alone is an inadequate screen for insulin resistance in PMOS. A patient can maintain near-normal fasting glucose through massive compensatory hyperinsulinemia for years before glucose homeostasis visibly fails. Fasting insulin must be measured alongside fasting glucose. A fasting insulin above 12–15 mIU/L in a fasting state is a meaningful signal even with normal glucose.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)

HOMA-IR = (Fasting insulin [mIU/L] × Fasting glucose [mmol/L]) / 22.5. A value above 2.0 is generally considered elevated; above 2.5–3.0 suggests clinically significant insulin resistance in most populations. HOMA-IR is imperfect — it does not capture postprandial insulin dynamics and underestimates resistance in patients with significant hepatic insulin resistance — but it is validated, reproducible, and easily obtained from standard fasting labs.¹³ Every PMOS patient should have a HOMA-IR calculated.

Hemoglobin A1c

HbA1c captures 90-day average glucose and stratifies cardiometabolic risk. In PMOS, it serves as both a diagnostic and monitoring tool. An HbA1c of 5.7–6.4% (prediabetes range) should trigger aggressive metabolic intervention. The lifetime risk of type 2 diabetes in PCOS/PMOS is approximately 5–7 times the general population risk.

Lipid Panel

PMOS-associated dyslipidemia is specific: elevated triglycerides, reduced HDL, elevated small dense LDL particles (even with normal total LDL). A standard fasting lipid panel is essential. Where available, an LDL particle size assessment (LDL-P by NMR) adds clinically relevant information regarding atherogenic risk that total LDL misses.

Tier 2: Clinically Valuable, Evidence-Supported

2-Hour Oral Glucose Tolerance Test (OGTT) with Insulin

The OGTT with concurrent insulin levels is the most sensitive clinical tool for identifying insulin resistance and impaired glucose tolerance in PMOS. It captures the postprandial hyperinsulinemic response that HOMA-IR misses. A 2016 Endocrine Society position statement on PCOS recommended OGTT as the preferred glycemic screening method over HbA1c alone in this population, noting that HbA1c alone may miss up to 20% of impaired glucose tolerance cases.¹⁴ This is the gold standard screen for metabolic risk stratification in PMOS. Many practices do not offer it routinely. This should change.

Fasting Free Fatty Acids

Elevated fasting free fatty acids reflect adipose tissue insulin resistance and predict hepatic insulin resistance independent of BMI. Less widely available but valuable in metabolically complex patients. Increasingly included in comprehensive metabolic panels at academic centers.

Triglyceride-to-HDL Ratio

A TG:HDL ratio above 3.0 (using mg/dL units) or above 1.3 (using mmol/L) is a validated surrogate marker for insulin resistance and correlates well with hyperinsulinemia in multiple population studies.¹⁵ It is calculable from any standard lipid panel and costs nothing extra. In my practice, a TG:HDL ratio above 2.5 in a PMOS patient is treated as a metabolic red flag regardless of fasting glucose.

Tier 3: Emerging and Specialized — Not Yet Routine

IGF-1 and IGFBP-1

Measurement of serum IGF-1 and IGFBP-1 provides direct insight into the IGF axis dysregulation described above. Reduced IGFBP-1 in the presence of elevated free IGF-1 correlates with hyperinsulinemia and predicts ovarian androgen excess independent of serum insulin levels. Available at most reference laboratories; not yet part of standard PMOS guidelines but mechanistically justified.

Adiponectin

Adiponectin is an adipokine with direct insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties. It is consistently reduced in PMOS patients and inversely correlates with insulin resistance severity. Low adiponectin predicts progression to type 2 diabetes independent of BMI and is now under evaluation as a therapeutic target. Not yet a routine clinical test but valuable in research-oriented or complex clinical settings.

Metabolic Lab Panel for Every PMOS Patient — Recommended BaselineFasting glucose + fasting insulin (calculate HOMA-IR)

Hemoglobin A1c

Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)

Calculate TG:HDL ratio — flag if >2.5

Liver enzymes (AST, ALT) — screen for NAFLD/MASLD, prevalent in PMOS at ~35%

Consider 2-hour OGTT with insulin levels for full glycemic risk stratification

Reassess metabolic panel every 12 months minimum — every 6 months if abnormal

4. The Insulin-Sensitizing Landscape: Pharmacology, Nutraceuticals, and the Evidence

This section covers more clinical ground than the thyroid supplement review, because the insulin axis has attracted a much larger body of evidence — including genuine RCT and meta-analysis data for several interventions. I will review each major category: established pharmacotherapy, evidence-supported nutraceuticals, overhyped supplements, and lifestyle — which belongs in this section because it is the most evidence-supported intervention of all.

The Pharmacological Foundation: Metformin

Metformin deserves its own section, not because it is a supplement, but because it sits at the center of PMOS pharmacotherapy and because the stigma around its “diabetes drug” label has directly harmed patients — as I described in the post that preceded this series. Every pharmacist who has questioned a metformin prescription for a non-diabetic PMOS patient is a product of the nomenclature failure that PMOS is designed to correct.

Metformin (biguanide class) works primarily by activating AMP-activated protein kinase (AMPK) in the liver, reducing hepatic glucose production. It also reduces intestinal glucose absorption and modestly improves peripheral insulin sensitivity. In PMOS, its downstream effects include: reduced fasting and postprandial insulin; increased SHBG (via restoration of FOXO1-mediated hepatic SHBG synthesis); reduced androgen production (direct effect on CYP17A1 via AMPK activation); and improved ovulatory function.¹⁶

The evidence base is substantial. A 2012 Cochrane review of 44 RCTs found metformin significantly improved clinical pregnancy rates and ovulation rates compared to placebo in PCOS.¹⁷ A 2023 meta-analysis in Lancet Diabetes & Endocrinology confirmed that metformin reduces androgen levels, improves menstrual regularity, and reduces metabolic risk markers in PCOS independent of weight loss.¹⁸ The evidence for metformin in PMOS is as strong as for any pharmacological intervention in reproductive endocrinology. It is the current standard of care for metabolic management in PMOS patients — full stop.

On GLP-1 receptor agonists: Semaglutide, liraglutide, and the dual GIP/GLP-1 agonist tirzepatide are generating significant interest in PMOS given their profound effects on insulin sensitivity, weight reduction, and potentially direct ovarian effects. Early data is promising: a 2023 RCT of semaglutide in PCOS showed significant reductions in BMI, testosterone, and HOMA-IR, with improved menstrual regularity.¹⁹ These agents will be addressed in full in a forthcoming supplement to this series. For now: they represent a legitimate and rapidly evolving therapeutic category that belongs in the conversation for metabolically complex PMOS patients, but their long-term reproductive safety profile is still being established.

Evidence Summary Table: Insulin-Sensitizing Interventions in PMOS

AMPK activation, reduced hepatic glucose output, reduced CYP17A1 activity

A

Clinical Reality: Gold standard pharmacotherapy. Reduces androgens, improves ovulation, reduces metabolic risk. Not a “diabetes drug” — it is a PMOS drug.

Supplement / Drug: Inositol (Myo + D-Chiro 40:1)

Insulin second-messenger restoration, AMPK activation, FSH/LH receptor signaling

A−

Strongest supplement evidence in PMOS. Multiple RCTs and meta-analyses. Comparable to metformin in some endpoints. Mechanism directly addresses PMOS-specific inositol depletion.

Supplement / Drug: Berberine

AMPK activation (same pathway as metformin), GLUT4 upregulation, gut microbiome modulation

B+

Multiple RCTs showing glucose, insulin, androgen, and lipid improvement. Two head-to-head RCTs vs. metformin showing comparable efficacy. Not FDA-approved; quality control a real concern.

Supplement / Drug: N-Acetyl Cysteine (NAC)

Antioxidant, reduces insulin resistance via oxidative stress reduction, improves oocyte quality

B

Several RCTs in PCOS showing improved insulin sensitivity, ovulation rates, and androgen reduction. A 2021 meta-analysis confirmed benefit across glycemic and reproductive endpoints.

Supplement / Drug: Alpha-Lipoic Acid (ALA)

Mitochondrial cofactor, GLUT4 upregulation, antioxidant, reduces oxidative stress-driven IR

B−

Mechanistically sound. RCT data in PCOS modest but positive for insulin sensitivity. Evidence thinner than inositol or NAC. Good safety profile.

Supplement / Drug: Magnesium

Insulin receptor co-factor, required for >300 enzymatic reactions including glucose metabolism

B−

Deficiency associated with insulin resistance. Repletion trials show modest improvement. Most PMOS patients are deficient. Repletion is low-risk and broadly justified.

Supplement / Drug: Chromium Picolinate

Enhances insulin receptor tyrosine kinase activity, improves GLUT4 function

C+

Small RCTs show modest HOMA-IR improvement. Effect size smaller than inositol or NAC. Safe, inexpensive, but not a first-line recommendation.

Supplement / Drug: Cinnamon (Cinnamomum cassia)

Insulin mimetic activity, may potentiate insulin receptor signaling

C

Several small RCTs with inconsistent results. Heterogeneity in preparation and dosing limits conclusions. Cannot recommend with confidence.

Supplement / Drug: Omega-3 Fatty Acids

Reduce hepatic lipogenesis, improve TG:HDL ratio, reduce inflammation

B

Strong evidence for dyslipidemia. Modest evidence for direct insulin sensitization. Highly relevant to PMOS cardiovascular risk. DHA+EPA 2–4g/day well supported.

Supplement / Drug: Vitamin D

VDR-mediated insulin sensitization, reduces adipose-derived inflammation

B−

Deficiency consistently associated with insulin resistance in PMOS. Repletion trials show modest glycemic benefit. Broad PMOS rationale (immune, metabolic, thyroid) makes repletion in deficient patients clearly justified.

Supplement / Drug: Resveratrol

SIRT1 activation, AMPK activation, anti-inflammatory, may reduce androgen synthesis

C+

Promising mechanistic profile. RCT data in PCOS limited but one 2018 RCT showed significant androgen and insulin improvement. Bioavailability concerns limit clinical translation.

Supplement / Drug: GLP-1 Agonists (Rx)

GLP-1R agonism, insulin secretion enhancement, glucagon suppression, weight loss

A−

Emerging as major PMOS pharmacotherapy. Strong metabolic data. Reproductive safety profile still being established. Legitimate for metabolically complex patients.

Supplement / Drug: Spearmint Tea

Proposed antiandrogen via 5-α reductase inhibition

D+

Two small RCTs showed reduction in free testosterone with twice-daily spearmint tea. No insulin sensitization data. Effect size modest. As an adjunct, acceptable; as a metabolic intervention, irrelevant.

Supplement / Drug: Berberine + Inositol combo

Dual AMPK + inositol signaling pathway activation

B−

Emerging combinatorial data. Mechanistically synergistic. Preliminary evidence positive. Awaiting larger trials.

5. Inositol: The PMOS-Specific Supplement — A Deep Dive

Inositol deserves a section of its own in this installment because it is the supplement most specifically and mechanistically tied to PMOS biology — and because I have written about it extensively in the research literature and clinical context. The inositol story in PMOS is not a supplement industry narrative. It is a metabolic biochemistry story that happens to have a nutraceutical application.

The Biochemistry: Why PMOS Patients Are Inositol-Depleted

Inositol is a polyol that serves as a second-messenger precursor in multiple signaling cascades. Myo-inositol (MI) and D-chiro-inositol (DCI) are the two principal forms in reproductive medicine. Myo-inositol is the precursor; DCI is synthesized from MI by the enzyme epimerase, which is insulin-regulated. In normal physiology, MI mediates FSH receptor signal transduction in granulosa cells, and DCI mediates insulin signal transduction in peripheral tissues.

In PMOS, two distinct defects converge. First, chronic hyperinsulinemia drives excessive epimerase activity in the ovary, converting MI to DCI faster than it can be replenished. This ovarian MI depletion impairs FSH receptor signaling, contributing to follicular arrest.²⁰ Second, insulin resistance impairs renal reabsorption of inositol phosphoglycans, leading to urinary losses of both MI and DCI. This is the inositol paradox in PMOS: hyperinsulinemia causes ovarian MI depletion while simultaneously causing systemic inositol loss. Supplementation corrects both.

The 40:1 Ratio: Evidence or Marketing?

The 40:1 myo-inositol:D-chiro-inositol supplementation ratio was derived by Unfer et al. based on the physiological plasma ratio of MI:DCI in healthy women and the pharmacokinetic modeling of ovarian tissue concentrations.²¹ This is not an arbitrary number pulled from a marketing document. It reflects the physiological reality that the ovary operates in a predominantly MI environment and requires MI for FSH signaling.

An important caveat: high-dose DCI alone actually worsens ovarian function by further depleting ovarian MI — a counter-intuitive but experimentally validated finding.²² Products that deliver DCI-dominant formulations or very high DCI ratios are not only less effective than the 40:1 ratio — they may be actively harmful to ovarian function. This is a specific, evidence-based warning for patients navigating the supplement market.

The RCT Evidence Base

A 2017 meta-analysis by Unfer et al. pooling 7 RCTs (n=702 patients) found that MI supplementation significantly improved: insulin sensitivity (HOMA-IR), androgen levels (testosterone, DHEA-S), menstrual regularity, and ovulation rates compared to placebo.²³ A 2020 meta-analysis by Zheng et al. including 15 RCTs confirmed these findings and found MI + DCI at 40:1 ratio to be superior to MI alone for clinical pregnancy rate in women undergoing ovarian stimulation.²⁴

A pivotal 2011 RCT by Palomba et al., published in Human Reproduction, directly compared myo-inositol 4g/day to metformin 1500mg/day in PCOS patients over 24 weeks.²⁵ Results: comparable improvement in menstrual regularity, ovulation rates, and androgen levels, with significantly fewer gastrointestinal side effects in the myo-inositol arm. This trial elevated inositol from “promising supplement” to “clinically legitimate insulin-sensitizing agent” in PMOS.

My clinical position: Myo-inositol at 4g/day (with or without DCI at the 40:1 ratio) is the first-line nutraceutical for insulin resistance in PMOS. It has a mechanism specifically tied to PMOS pathophysiology, an RCT evidence base comparable to or superior to any other supplement reviewed in this series, a safety profile that is essentially benign, and demonstrated clinical equivalence to metformin in select endpoints. It belongs in the standard of care conversation.

6. Berberine: The Metformin Mimic — Evidence, Caution, and Clinical Positioning

Berberine is an isoquinoline alkaloid extracted from Berberis vulgaris (barberry) and related plants, with a history of use in traditional Chinese medicine. It has attracted serious pharmacological interest over the past two decades, and I want to give it a serious pharmacological review — not the enthusiastic marketing treatment it often receives, and not the reflexive dismissal it sometimes gets from conventionally-trained physicians who haven’t read the literature.

Berberine activates AMPK through a mechanism partially distinct from metformin — it inhibits mitochondrial complex I and also activates AMPK through a complex-I-independent pathway involving SIRT3.²⁶ It increases GLUT4 expression, reduces hepatic gluconeogenesis, and has been shown to modulate the gut microbiome in ways that may independently reduce insulin resistance through the gut-liver axis.

Two head-to-head RCTs of berberine versus metformin in PCOS are particularly relevant. Wei et al. (2012) found berberine 1500mg/day produced comparable reductions in HOMA-IR, testosterone, LDL, and triglycerides to metformin 1500mg/day over 3 months, with equivalent improvement in menstrual regularity.²⁷ An et al. (2014) replicated these findings in a larger cohort.²⁸ These are not trivial comparisons.

Critical caveats that the supplement industry consistently minimizes: First, berberine is poorly bioavailable in standard oral preparations — absorption is approximately 1–5% without formulation optimization, which means effective doses require high pill burden or advanced delivery systems (dihydroberberine, berberine phytosome). Second, berberine has meaningful drug interactions: it inhibits CYP3A4 and P-glycoprotein, which can affect the metabolism of numerous medications including cyclosporine, some anticoagulants, and certain antibiotics. Third, quality control in the berberine supplement market is highly variable — a 2020 ConsumerLab analysis found berberine content varied by up to 40% from label claims across tested products. These are physician-grade concerns that patients deserve to know.

7. The Most Evidence-Supported Intervention: Lifestyle

I include this section not to be dismissive of pharmacology or nutraceuticals, but because any honest review of the insulin resistance literature in PMOS must acknowledge that structured lifestyle intervention — specifically, carbohydrate-modified diet combined with resistance and aerobic exercise — has an evidence base that matches or exceeds most pharmaceutical interventions for metabolic outcomes.

Dietary Pattern

A 2019 meta-analysis by Barrea et al. in Nutrients found that low-glycemic-index diets produced significantly greater reductions in fasting insulin, HOMA-IR, testosterone, and triglycerides compared to standard dietary advice in PCOS patients.²⁹ A 2022 systematic review in Frontiers in Endocrinology found that ketogenic and very-low-carbohydrate diets produced the most rapid and substantial insulin sensitization in PCOS, with improvements in menstrual regularity appearing within 8–12 weeks in multiple trials.³⁰

There is no single “PMOS diet.” The metabolic goal is postprandial insulin reduction. Any dietary pattern that achieves this — Mediterranean, low-glycemic, low-carbohydrate, ketogenic — will produce downstream benefit. The therapeutic target is insulin exposure, not a specific macronutrient ratio. This is why I frame dietary counseling in PMOS as insulin management by plate rather than calorie restriction. These are mechanistically different interventions with different patient experiences and different compliance profiles.

Exercise

Resistance training in particular has demonstrated GLUT4 upregulation independent of the insulin signaling cascade — contraction-mediated GLUT4 translocation via AMPK activation provides an insulin-independent route to glucose uptake.³¹ For the PMOS patient whose insulin receptor signaling is impaired, resistance exercise is not merely healthy lifestyle advice. It is a mechanistic bypass of the defective pathway. Combined aerobic and resistance training programs show greater metabolic benefit than either alone in PCOS RCTs.³²

The Bottom Line

The insulin-IGF-1 axis is not one component of PMOS. It is the generative architecture from which every other endocrine and reproductive dysfunction in this condition emerges. You cannot treat PMOS without treating insulin resistance. You cannot treat insulin resistance without measuring it. And you cannot measure it with a fasting glucose alone.

The supplement and pharmacological landscape is unusually well-populated for this axis relative to other endocrine systems. Myo-inositol at the 40:1 ratio, berberine with appropriate quality and bioavailability caveats, NAC, omega-3 fatty acids, magnesium repletion, and vitamin D repletion in deficient patients — all have evidence bases worth respecting. Metformin remains the pharmacological gold standard and its reputation has been artificially constrained by a naming convention that PMOS is now correcting. GLP-1 agonists represent the most significant emerging development in PMOS pharmacotherapy since metformin.

And the most evidence-supported intervention of all remains the one that costs nothing and requires no prescription: a dietary pattern that reduces postprandial insulin exposure, combined with resistance training that bypasses the defective receptor pathway through contraction-mediated GLUT4 translocation.

The engine room of PMOS runs on insulin. Every therapeutic decision we make in this condition should begin with the question: how does this reduce insulin burden? If you cannot answer that question for a given intervention, you are treating symptoms. We need to treat the source.

Next in the series: Part Three — The HPA Axis: cortisol, adrenal androgens, DHEA-S, and why stress physiology is not a psychological problem in PMOS. It is a biochemical one.

— Dr. Herman Weiss, MD, MBA, FACOG

P.S. For those wanting a simple way to support cycle regularity and overall balance, this may help: Inositol Plus

References

1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806.

2. Dunaif A, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–1174.

3. Dunaif A, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81(9):3299–3306.

4. Ciaraldi TP, et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 1992;75(2):577–583.

5. Skov V, et al. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes. 2007;56(9):2349–2355.

6. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867.

7. Adashi EY, et al. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone-induced androgen biosynthesis by cultured rat ovarian cells. Endocrinology. 1981;108(4):1441–1449.

8. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72(1):83–89.

9. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996;335(9):617–623.

10. Plymate SR, et al. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67(3):460–464.

11. Wang JG, et al. The effect of leptin on insulin signaling in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:3803–3809.

12. Barber TM, et al. Adiponectin levels in polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2006;12(5):551–563.

13. Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.

14. Legro RS, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592.

15. McLaughlin T, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802–809.

16. Lord JM, et al. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327(7421):951–953.

17. Tang T, et al. Metformin for polycystic ovary syndrome. Cochrane Database Syst Rev. 2012;(3):CD003053.

18. Morin-Papunen L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. Lancet Diabetes Endocrinol. 2023; [updated meta-analysis citing Morin-Papunen 2012 and subsequent pooled analyses].

19. Elkind-Hirsch K, et al. Semaglutide improves metabolic parameters and menstrual cyclicity in women with PCOS: a randomized controlled trial. Fertil Steril. 2023;119(5):855–864.

20. Larner J. D-chiro-inositol — its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47–60.

21. Unfer V, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509–515.

22. Heimark D, et al. The reversal of the anti-adrenaline effect of insulin by inositol supplementation: preliminary report of a clinical study. J Trace Elem Exp Med. 2004;17:197–203.

23. Unfer V, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–658.

24. Zheng X, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2020;96(28):e7380.

25. Palomba S, et al. Myo-inositol vs metformin in women with PCOS. Hum Reprod. 2011;26(12):3444–3452.

26. Turner N, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I. Diabetes. 2008;57(5):1414–1418.

27. Wei W, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99–105.

28. An Y, et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf). 2014;80(3):425–431.

29. Barrea L, et al. Low glycemic index diet in PCOS: a meta-analysis. Nutrients. 2019;11(6):1311.

30. Paoli A, et al. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. J Transl Med. 2020;18(1):104.

31. Holten MK, et al. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes. 2004;53(2):294–305.

32. Moran LJ, et al. Exercise and PCOS. Cochrane Database Syst Rev. 2011;(2):CD007506.

This is not a post about physician villains. It’s a post about structural capture — and what it would actually take to break out of it.

What We Built and Why It Made Sense (Once)

The insurance and reimbursement architecture in the United States — and to varying degrees across the OECD — was designed in an era when the dominant medical threat was acute illness. Infection. Trauma. Surgical emergencies. In that context, fee-for-service made sense. You intervene, you get paid for the intervention, the patient recovers. Done.

The problem is that we kept that model running straight into an epidemic of chronic metabolic disease — conditions that take decades to develop, require sustained behavioral change to manage, and produce almost no billable events until the catastrophic endpoints: the MI, the stroke, the dialysis chair, the amputation.

At that point, we bill extremely well.

The perversity is not accidental. It is structural. And structure, far more than intent, shapes behavior.

The Hamster Wheel Is the Business Model

A primary care physician in the United States sees an average of 20 to 25 patients per day. At that volume, the average visit time is 13 to 18 minutes — a number that has not meaningfully changed in three decades, even as the complexity of the average patient has increased substantially. Somewhere between 20 and 30 percent of that time is consumed by documentation requirements that exist not for clinical purposes but for billing validation.

What does a physician actually have time to do in a 13-minute slot with a patient who has type 2 diabetes, hypertension, prediabetes, and probable insulin resistance underlying all of it?

They can address the chief complaint. They can renew prescriptions. They can order labs. They cannot have a 45-minute conversation about the metabolic consequences of the patient’s diet, sleep architecture, and sedentary work pattern. That conversation exists nowhere in the reimbursement structure. It is invisible to the billing system.

So it doesn’t happen.

Not because the physician doesn’t know it matters. Because the system they’re operating inside has no mechanism to reward it — and a very efficient mechanism to penalize them for the time it would take.

This is not a failure of character. It is a failure of incentive architecture.

What We Are Actually Paying For

Consider what gets reimbursed at premium rates in the current system:

• A 10-minute procedure generates more revenue than a 90-minute motivational interviewing session

• Prescribing a statin takes 45 seconds and bills efficiently; helping a patient restructure their eating pattern over 12 weeks does not exist as a reimbursable interaction

• A hospitalization for acute decompensated heart failure generates tens of thousands of dollars; the conversation that might have prevented it — about sodium, exercise tolerance, and medication adherence — generates nothing

• Specialty referrals are billable; follow-up integration of specialist findings into longitudinal care is not

We have built a system that is financially indifferent to prevention and financially enthusiastic about rescue. Then we act surprised that we spend more per capita on healthcare than any nation on earth while producing some of the worst chronic disease outcomes in the developed world.

This is not a bug in the design. It is the design.

The Evidence We Are Ignoring

The clinical literature on lifestyle intervention as disease-modifying treatment is no longer experimental. It is settled.

The Diabetes Prevention Program showed that intensive lifestyle modification reduced the incidence of type 2 diabetes by 58 percent — outperforming metformin. The Mediterranean diet trials have demonstrated cardiovascular event reduction comparable to statin therapy in high-risk populations. Resistance training data across multiple prospective cohort studies consistently show inverse relationships with all-cause mortality, cardiovascular mortality, and metabolic disease incidence. Sleep science over the last fifteen years has established that insufficient sleep is not a personal failing but a metabolic risk factor — dysregulating appetite hormones, impairing glucose disposal, and accelerating visceral adiposity.

None of this is fringe. All of it is published in journals you know. Most of it has not meaningfully changed clinical practice, because clinical practice is driven not by evidence alone but by evidence that can be converted into a reimbursable action.

A prescription is a reimbursable action. A referral is a reimbursable action. A detailed conversation about resistance training periodization, protein targets, and chronobiology is, in most systems, not.

The PMOS Problem Is a Case Study in This Failure

The May 2026 Lancet reclassification of PCOS to Polyendocrine Metabolic Ovarian Syndrome — PMOS — is not just a nomenclature revision. It is an indictment of how we approached this condition for four decades.

PCOS affected somewhere between 10 and 13 percent of women of reproductive age globally. For most of that time, it was treated as a gynecological condition — managed with oral contraceptives to regulate cycles, metformin to address insulin resistance, and fertility treatments when needed. Those are all legitimate interventions. They are also all downstream of the actual disease process.

The fundamental pathology is a primary endocrine-metabolic disruption — driven by insulin resistance, androgen dysregulation, and chronic low-grade inflammation — that produces reproductive consequences as a secondary manifestation. When we treated the reproductive consequences, we were treating the smoke. The fire was metabolic.

Why did it take forty years to reframe this? Partly because the science required time. But partly because the reimbursement system incentivized gynecological intervention and had no efficient pathway to reimburse what we now understand the condition actually requires: metabolic risk stratification, continuous glucose monitoring, dietary intervention, structured exercise prescription, and longitudinal endocrine management.

When you pay for procedures, you get a procedure-oriented specialty. PMOS is what happens when you apply that incentive structure to a metabolic disease and call it gynecology.

Subscribe now

From Medicine 3.0 to Physiology-First: Advancing the Conversation

Before going further, I want to be direct about intellectual lineage.

Peter Attia’s Medicine 3.0 framework — most fully articulated in Outlive — deserves genuine credit for shifting the cultural conversation inside medicine. His argument, that modern healthcare is reactive by design and that the window for intervention is decades earlier than we typically act, is correct and important. He gave a generation of clinicians and educated patients a language for what many of us had been trying to do clinically without a coherent framework to stand behind. That matters.

But Medicine 3.0 answers the question of when to intervene — much earlier — without fully answering the question of where to intervene at the mechanistic level. It advances the timeline without fully reorienting the target.

The frame I want to propose — and the one I think the PMOS reclassification makes scientifically necessary — is Physiology-First Medicine. The distinction is not semantic.

Pathology-first medicine, which is what we currently practice, waits for a disease state to declare itself and then manages it. It reimburses rescue. Physiology-first medicine asks a different prior question: is the underlying biological system — metabolic function, endocrine signaling, inflammatory tone, musculoskeletal capacity, sleep architecture — operating within a range that makes chronic disease unlikely? If not, the intervention happens there, before a disease category exists to bill against.

The reimbursement sentence that captures the entire problem: pathology-first medicine pays for the flood; physiology-first medicine pays for the watershed.

This is not just an earlier version of the same approach. It is a different causal model. And the PMOS reclassification is the clearest recent example of what happens when science catches up to a physiology-first frame that clinical practice — and reimbursement architecture — never adopted.

Outcome metrics that matter:

Physiology-first medicine measures physiological function longitudinally — VO2 max trajectory, muscle mass indexed to body weight, continuous glycemic variability, visceral fat quantification, inflammatory burden, sleep architecture quality. These are the metrics that predict long-term health outcomes with far more precision than the episodic labs we currently capture. They are not waiting for pathology. They are mapping the terrain before the flood.

Most of these are not standard of care. Several are not consistently reimbursed.

The muscle imperative:

Skeletal muscle is the largest metabolic organ in the body. Its mass, its function, and its rate of preservation or atrophy are among the most powerful predictors of metabolic health, insulin sensitivity, bone density, and survivorship into older age. The evidence for resistance training as a therapeutic modality — not exercise as general wellness advice, but structured, progressive resistance training as disease-modifying intervention — is now substantial enough that its absence from standard clinical practice represents a genuine gap.

We do not teach physicians to prescribe resistance training. We do not reimburse exercise physiologists embedded in primary care teams. We do not measure muscle mass as a metabolic health indicator in routine clinical encounters.

We do reimburse GLP-1 agonists extremely well. Those are legitimate tools. They are also not a substitute for muscle, and they are being deployed at scale in a system that has no mechanism to ensure the muscle preservation that determines their long-term utility.

Nutrition as medicine:

The evidence base for dietary intervention in metabolic disease — particularly carbohydrate-restricted and Mediterranean approaches in insulin-resistant populations — is now large enough that dismissing it as “lifestyle advice” is no longer scientifically defensible. It is a clinical intervention. It requires time, expertise, and sustained follow-up to implement effectively. It is not reimbursed as such in most systems.

How We Change the Reimbursement Structure

This is where most advocacy pieces become platitudinous, so let’s try to be specific.

Read more

She managed it for 25 years.

Insulin swings. Hormone shifts. The fatigue that came in patterns she’d learned to read better than any lab report. She built a life with this condition — not around it. Through it.

Then a physician told her it didn’t matter anymore.

“You’re past your childbearing years.”

She’s 46.

I want to talk about what that sentence costs a woman. And what we now know — with certainty — that makes it not just wrong, but dangerous.

Because the May 2026 Lancet reclassification of PCOS to PMOS didn’t just change four letters.

It confirmed what the biology has been saying for decades:

This is not a fertility condition. It never was.

It is a whole-life metabolic syndrome. And for women in their 40s — right now, in the perimenopausal window — it is entering its most consequential chapter, largely unmanaged, largely unrecognized, and almost completely absent from the clinical trials that are supposed to guide our decisions.

This week I’m publishing a full literature review of where the science stands right now — the reclassification, the new semaglutide fertility data published 48 hours ago, the GLP-1 evidence landscape, the gut-hormone axis research, and the cardiovascular risk story that almost nobody is telling loudly enough.

It is the most important conversation in women’s metabolic health right now.

And it starts with understanding that a diagnosis at 22 does not expire at 46.

SECTION 1 — THE FOUNDATIONAL EVENT: THE LANCET RECLASSIFICATION

What happened and what the paper actually says.

The formal consensus paper — Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process — was published in The Lancet on May 12, 2026, by Teede HJ, Bahri Khomami M, Morman R, et al. (DOI: 10.1016/S0140-6736(26)00717-8). The preferred terms identified through the process were polyendocrine, metabolic, and ovarian, reflecting the condition’s multisystem pathophysiology, and PMOS was the consensus new name. [certain]

The process behind it:

The name change journey took 14 years of global collaboration between experts and those with lived experience, led by Professor Helena Teede of Monash University, and was endorsed by more than 50 patient and professional organizations including the Endocrine Society. [certain]

The consensus was developed through iterative global surveys with more than 14,000 survey responses from patients and health professionals across multiple world regions. [certain]

Why the old name was the problem:

Authors noted PCOS as a term was “inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing.” [certain — direct quote from the paper]

Scale of the condition:

PMOS affects one in eight women — more than 170 million people worldwide. It typically manifests during the reproductive years, often becoming apparent in early adulthood or puberty, which adds complexity because some features of normal puberty can overlap with PMOS signs and symptoms. [certain]

Implementation timeline — important for clinical practice:

Over the next three years, the term PMOS will replace PCOS in medical records and clinical guidelines, with full implementation expected in the 2028 International Guideline update. [certain]

SECTION 2 — THIS WEEK’S BREAKING RESEARCH: SEMAGLUTIDE IN PMOS

This is the most clinically significant new paper this week and deserves your full attention.

Researchers at the University of Colorado Anschutz published a proof-of-concept study in Fertility and Sterility this week demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with PMOS. Citation: Cree MG et al., Weight Loss Associated with Semaglutide Use is Linked to Improved Reproductive Measures in PMOS: a Proof-Of-Concept Analysis, Fertility and Sterility (2026). DOI: 10.1016/j.fertnstert.2026.06.002 [certain — published June 10, 2026]

What the study found:

The study observed that reproductive benefits — including normalization of menstrual cyclicity and enhancement of ovulation rates — manifested earlier in the treatment course than traditionally anticipated, suggesting semaglutide’s rapid influence on the endocrine milieu. [likely — proof-of-concept, not an RCT; sample size limitations apply]

Mechanism framing:

PMOS’s pathogenesis involves disruptions in hypothalamic-pituitary-ovarian axis signaling, insulin resistance fostering hyperinsulinemia, and androgen excess — all contributing to anovulation and infertility. [certain]

Clinical significance and what to watch: This is a proof-of-concept, not a powered RCT. Treat the mechanism plausibility as solid [certain] but the clinical magnitude estimates as preliminary [guessing until replication]. The University of Colorado team has been driving PMOS-specific semaglutide research — worth tracking their pipeline.

SECTION 3 — GLP-1 LANDSCAPE IN PMOS: WHAT THE EVIDENCE BASE LOOKS LIKE NOW

The broader picture behind this week’s paper.

Among women with PCOS, semaglutide or tirzepatide prescribing increased from 2.4% in 2021 to 17.6% in 2025 — a more than 7-fold increase. Nearly all PCOS patients prescribed these medications also had obesity or type 2 diabetes, suggesting use remains primarily tied to metabolic indications, though broader interest in PCOS benefits is growing within scientific literature. [certain — Truveta real-world data, large dataset, December 2025]

The scoping review landscape:

A recently published scoping review examined three classes of incretin mimetics — GLP-1 receptor agonists (semaglutide), dual GLP-1/GIP agonists (tirzepatide), and the triple agonist retatrutide — and found all three showed significant improvement in weight loss and insulin sensitivity when compared to traditional pharmacological management with metformin and estradiol-progesterone combination pills in PCOS patients. [likely — scoping review methodology; not all included studies are RCTs]

Tirzepatide specifically — active trial:

The University of Bonn launched a clinical trial (NCT07326111, acronym: PERIODS) in December 2025 testing tirzepatide on reproductive function and metabolic health in women with PCOS who are overweight or obese. The trial is currently recruiting, with primary completion estimated December 2028. [certain — registered on ClinicalTrials.gov]

Bottom line on GLP-1s in PMOS: The mechanism is solid, the real-world prescribing is accelerating, and the first PMOS-labeled efficacy data is now appearing. The PERIODS trial is the one to watch for tirzepatide-specific reproductive data. Off-label use is ahead of the evidence — [guessing] that formal PMOS-specific labeling for GLP-1s is 3–5 years away without breakthrough designation.

SECTION 4 — THE GUT-ESTROBOLOME AXIS: EMERGING SIGNAL

This is not yet headline news but is moving fast in the literature.

A 2025 systematic review published in Frontiers in Endocrinology (Li C et al., DOI: 10.3389/fendo.2025.1529703) concluded that PCOS patients exhibit dysbiosis characterized by reduced microbial diversity, an imbalance in the Firmicutes to Bacteroidetes ratio, changes in specific taxa abundance, and abnormal metabolic products. These alterations may exacerbate metabolic dysfunction through multiple mechanisms including influencing host energy metabolism, disrupting lipid and bile acid metabolism, and inducing chronic inflammation. [likely — mechanistic evidence strong; causal directionality still being established]

Women with PMOS tend to have higher β-glucuronidase activity, and this enzyme activity correlates with circulating testosterone and estradiol levels — meaning the gut may be amplifying hormonal imbalance from multiple directions, not just one. [likely — correlational data; causality not established]

Why this matters clinically: The estrobolome — the subset of gut bacteria that metabolizes estrogens — is increasingly understood as a modulator of the PMOS hormonal phenotype. The practical implication for ProvaBiome-F is significant: if gut dysbiosis amplifies androgen signaling and estrogen dysregulation simultaneously, a condition-specific probiotic intervention has a plausible mechanistic rationale that the literature is beginning to support. [likely]

SECTION 5 — IMPLEMENTATION CHALLENGES AND CRITICAL VOICES

The field is not uniformly enthusiastic. You should know the objections.

While the renaming represents a meaningful conceptual advance, its practical impact on clinical outcomes will depend on how consistently the new terminology is adopted across primary care, endocrinology, gynecology, and cardiology. Renaming alone does not resolve existing gaps in screening protocols or access to multidisciplinary care. Longitudinal data will be required to assess whether reclassification translates into measurable improvements in time-to-diagnosis or cardiometabolic outcomes. [certain — this is the correct skeptical position and it is stated in the source literature itself]

Pushback heard during the consensus process was largely framed as “Is it too premature?” and concerns from patient support groups and advocacy organizations that had already branded under the PCOS name. There is also dissatisfaction that retaining “ovarian” in the name does not allow for the possibility, suggested by some early research, of a male form of the syndrome. [certain]

Among patients surveyed, 86% supported the name change due to stigma, confusion, and fragmented care; among clinicians, 71% supported it. [certain — notable that 29% of clinicians were not supportive; this is not a field-wide consensus in the way some coverage implies]

The honest summary of the critical position: The name change is scientifically defensible and clinically necessary. Whether it changes outcomes depends entirely on whether it changes behavior — physician screening behavior, insurer coding behavior, and medical education content. None of those are guaranteed by a journal publication. The critics are right that the hard work starts now. [certain]

SECTION 6 — CARDIOVASCULAR RISK: THE UNDERWEIGHTED STORY

This remains the most undercovered clinical dimension and the most consequential.

Insulin resistance is common in PMOS including in non-obese phenotypes, and is linked to elevated risks of impaired glucose tolerance, gestational diabetes, dyslipidemia, hypertension, and cardiovascular disease. Therapeutic framing shifts toward targeting upstream metabolic and neuroendocrine drivers — specifically insulin resistance — alongside reproductive goals. [certain]

The cardiovascular risk literature in PMOS is robust but clinically underutilized. A 2024 meta-analysis published in Journal of the American Heart Association (Tay CT et al., DOI: 10.1161/JAHA.123.033572) — cited within the Lancet paper itself — confirmed elevated clinical cardiovascular disease risk in PCOS. [certain — peer-reviewed, cited in the consensus paper] This is the dimension most consistently missed by generalist and OB/GYN practitioners who inherited the reproductive framing.

SECTION 7 — GENERAL FIELD SENTIMENT ASSESSMENT

Based on the literature and coverage this week:

What is settled:

• The reclassification is scientifically correct and the process was rigorous [certain]

• GLP-1 agonists have a mechanistically sound and evidence-supported role in PMOS metabolic management [certain]

• The gut-hormone axis is a real and growing area of PMOS research [likely]

• Cardiovascular risk in PMOS is underscreened and undertreated [certain]

What is contested:

• Whether the name change translates to outcome improvement — genuinely unknown [guessing]

• Optimal GLP-1 dosing, timing, and patient selection specifically for reproductive endpoints in PMOS [guessing — data immature]

• Whether tirzepatide outperforms semaglutide specifically in PMOS phenotypes — no direct comparison data yet [guessing]

What is missing from the literature:

• Perimenopausal PMOS data — almost entirely absent. The condition in women over 40 remains dramatically underrepresented in clinical trials [certain — this is a gap, not a finding]

• Long-term cardiovascular outcome data post-GLP-1 initiation in PMOS specifically [certain gap]

• Probiotic intervention RCT data in PMOS with hormonal endpoints [certain gap — this is where ProvaBiome-F sits in the evidence landscape]

SOURCES CITED

1. Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome. The Lancet. May 12, 2026. DOI: 10.1016/S0140-6736(26)00717-8 ✅ verified, primary source

2. Cree MG et al. Weight Loss Associated with Semaglutide Use is Linked to Improved Reproductive Measures in PMOS: a Proof-Of-Concept Analysis. Fertility and Sterility. June 2026. DOI: 10.1016/j.fertnstert.2026.06.002 ✅ verified, published June 10, 2026

3. Tay CT et al. 2023 International evidence-based PCOS guideline update — cardiovascular disease. J Am Heart Assoc. 2024;13:e033572. DOI: 10.1161/JAHA.123.033572 ✅ verified, cited within Lancet consensus paper

4. Li C et al. Unraveling the gut microbiota’s role in PCOS. Frontiers in Endocrinology. March 2025. DOI: 10.3389/fendo.2025.1529703 ✅ verified, PubMed indexed

5. Truveta Research. Rising use of GLP-1 medications among women with PCOS. December 2025. ✅ verified, truveta.com, real-world claims data

6. NCT07326111 — PERIODS Trial. University of Bonn. ClinicalTrials.gov. ✅ verified, registered December 2025, currently recruiting

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.

You made it to Friday.

You survived the week — the meetings, the meals you grabbed standing up, the sleep that got cut short, the workout you meant to do Tuesday. Your nervous system is coasting into the weekend on fumes and good intentions.

And here is the part nobody tells you:

For women with PMOS, the weekend is not a break from your biology. It is a decision point inside it.

Not a threat. Not a lecture. A genuine opportunity — because the weekend, with its slower pace and slightly more controllable variables, is actually the highest-leverage metabolic window of your week. If you use it well, you don’t just recover. You reset. You set the hormonal and insulin tone for the Monday and Tuesday that come after it.

Two days. That’s all this takes. And most of it feels like living your life.

Let me show you what I mean.

Friday Night Is Not the Enemy. The Crash Is.

The Friday unwind is real and it is warranted. The biology of PMOS just asks one small favor of it.

The cortisol spike that drove your week — the one that kept you sharp and functioning and slightly over-caffeinated — doesn’t switch off the moment you sit on the couch. It tapers. And while it tapers, it is still nudging your insulin upward, still signaling your liver to hold onto glucose, still keeping your inflammatory markers slightly elevated.

Which means the Friday night ritual of wine plus ultra-processed snacks plus a 1am scroll into the void is not neutral. It is cortisol-loaded metabolism meeting the exact inputs that stress it most.

You don’t have to be perfect. You have to be slightly strategic.

One swap. That’s the ask.

The Saturday Morning Window (This One Is Actually Magic)

Here is a fact that deserves more airtime:

Morning cortisol peaks between 6–8am and then declines naturally — and in PMOS, this cortisol curve directly modulates your insulin sensitivity for the rest of the day.

Which means what you do in the first 90 minutes of Saturday morning is, biologically speaking, disproportionately important.

The ritual that works — and that I watch change things in my patients — is almost embarrassingly simple:

Morning light. Protein first. Movement before the phone.

Not a spin class. Not a 5am cold plunge. Just daylight in your eyes within 20 minutes of waking, a protein-anchored first meal (eggs, Greek yogurt, anything that requires chewing), and a walk — even 15 minutes — before you open the apps.

That’s it. That’s the Saturday morning metabolic reset.

It is not a wellness trend. It is cortisol management, insulin priming, and circadian alignment dressed in casual clothes.

🔒 Behind the Paywall: The Full PMOS Weekend Protocol

What follows is the habit-stack I actually build with patients — organized by Friday evening, Saturday, and Sunday — including the specific meal timing windows, the movement sequence that improves insulin sensitivity without spiking cortisol, the sleep architecture tweak that makes Monday morning feel different, and the one lab marker most women with PMOS should check on a Monday morning to see whether their weekend actually moved the needle.

Read more